Current Funding Opportunities for Scientists

Lists of funding opportunities are updated weekly. New funding opportunities for scientists are distributed in the VPRI Update newsletter.

To submit funding opportunities, and/or be added to the VPRI Update mailing list, please send your request to VPRI@unityhealth.to

Opportunities are categorized by Sponsor Type (Tri-Agency, Other Canadian, International & NIH). Filter opportunities by keyword (e.g. Sponsor Type, CIHR, user-supplied keyword, etc.) using the Search box at right.

Sponsor TypeFunding Program TitleAmount and DurationDescription Deadline
Tri-AgencyCIHR Operating Grant: 17th JPIAMR transnational call for research projectsUp to $166,667 per year as a team partner; up to $200,000 per year as a team coordinator. Three-year term.The specific objectives of this funding opportunity are to:
• Design novel or improved interventions to prevent, mitigate and /or treat fungal infections, which are resistant to treatments and/or are at risk of developing resistance.
• Improve and/or compare and/or evaluate strategies, technologies, treatments, methods, protocols or data collection based on existing interventions, aiming to prevent or reduce the emergence or spread of antibacterial or antifungal resistance or to treat/cure infections caused by resistant bacteria/fungi and recommend new policies.
Applicants must consult the AMR Interventions 2024 call on the JPIAMR website for complete details on the objectives.
Pre-Proposal: March 3, 2024;
Application (by invitation): July 9, 2024.
Tri-AgencyCIHR Operating Grant: EU Joint Programme - Neurodegenerative Disease Research (JPND) Up to $111,000/year for up to 3 years.The JPND launched this joint transnational call with the aim of improving the understanding of disease mechanisms and advancing measurability of disease progression at early and pre-symptomatic stages of neurodegenerative diseases. Proposals to this call must be ambitious, innovative, multi-disciplinary and multi-national (i.e. include research teams from at least three different countries). They must be hypothesis driven and should have a strong focus on methodology.Pre-proposal: March 5, 2024.
Full proposal: June 25, 2024.
Tri-AgencyCIHR Team Grant: Controlled Substance Use Trends and Population EstimatesUp to $2,000,000 per year for up to 4 years.The specific objectives of this funding opportunity are to:
• generate new and ongoing population estimates of the use of controlled substances in Canada;
• generate new and ongoing knowledge of trends related to controlled substances from wastewater analyses and from other relevant sources in jurisdictions across Canada; and
• ensure the sharing of the generated population estimates and real-time trends of the use of controlled substances with local, provincial, territorial, national and international knowledge users, through a publicly accessible website.
The Nominated Principal Applicant to this funding opportunity must be a member of the CRISM Network
March 21, 2024.
Tri-AgencyCIHR operating grant: Human Frontier Science Program – Research Grants--This opportunity supports innovative basic research into fundamental biological problems with emphasis placed on novel and interdisciplinary approaches that involve scientific exchanges across national and disciplinary boundaries. Projects are expected to be at the frontiers of knowledge and therefore entail risk. Participation of scientists from disciplines outside the traditional life sciences such as biophysics, chemistry, computational biology, computer science, engineering, mathematics, nanoscience or physics is recommended. Two types of Research Grants are available:
• Early Career Grants: Awarded to teams of researchers, all of whom are within the first five years after obtaining an independent laboratory (e.g. Assistant Professor, Lecturer or equivalent). Applications for Early Career Grants will be reviewed in competition with each other, independent of applications for Program Grants.
• Program Grants: Awarded to teams of independent researchers at any stage of their careers. Applications including independent investigators early in their careers are encouraged.
Letter of intent: March 28, 2024.
Full application (by invitation): September 2024.
Tri-AgencyCIHR Operating Grant: Network Environment for Indigenous Health Research Centre - Development Grant (Yukon)Up to $75,000 for 1 year.This development grant will provide support for development activities, including community personnel support and travel support to attend gatherings of Indigenous communities, researchers, knowledge users, stakeholders, and/or partners, in preparation of a Yukon NEIHR Centre Operating Grant application.April 3, 2024.
Tri-AgencySickKids Foundation-CIHR Operating Grant: New Investigator Grants in Child and Youth Health (2024)Up to $100,000 per year for up to 3 years.This supports new investigators for research in biomedical, clinical, health systems and services, population and public health sectors that has the potential for significant impact on children's health outcomes. As of the application deadline, the applicant:
• As a principal investigator has not been awarded combined Operating Grant funding of $500,000 or more Canadian dollars.
• Is within 5 years of their first academic appointment. Time taken for breaks in research career, including COVID-caused delays, will be considered in determining eligibility as a new investigator.
• Has at least 50% of protected research time for the duration of the project.
Visit the New Investigator Research Grants funding opportunity on the SickKids Foundation website for further details
April 22, 2024.
Tri-AgencyCIHR Operating Grant: Knowledge Mobilization in Diabetes Prevention and TreatmentUp to $125,000 for up to one year.The goal of this funding opportunity is to enhance knowledge mobilization in the field of diabetes, focusing on evidence integration into health services, programs, and policies. The objectives of this funding opportunity are to:
• Increase and enhance bi-directional mobilization of knowledge and integration of evidence into policies and practices related to diabetes prevention, remission, screening, diagnosis, management, treatment, and delivery of care for all types of diabetes as well as screening and prevention of diabetes complications.
• Support researchers and knowledge users in the development and implementation of a knowledge mobilization plan to address a health system priority and/or identified evidence needs or gaps.
• Facilitate uptake of evidence to improve the lives of people at risk of or living with diabetes in Canada.
Webinar: CIHR will be hosting a webinar to inform participants about the requirements of this funding opportunity; please check the webinars page once the funding opportunity is launched.
May 1, 2024.
Tri-AgencyCIHR Catalyst Grant: STBBI Research in Canada: Beyond HIV/AIDS and Hepatitis CUp to $100,000 per year for one year.The overall goal of this grant is to strengthen the current landscape of STBBI research in Canada, and to build capacity and spur innovation in this field, with a specific focus on STBBI of public health relevance beyond the fields of HIV and hepatitis C and in alignment with the CIHR HIV/AIDS and STBBI Strategic Plan 2022-2027. This funding opportunity will support projects across all pillars of research (biomedical research; clinical research; health services research; and social, cultural, environmental, and population health research) with a primary focus on STBBI of public health relevance including, but not limited to:
Chlamydia, Gonorrhea, Syphilis, Hepatitis B, Human papillomavirus (HPV). Research projects focusing primarily on HIV or hepatitis C will not be eligible for funding.
May 9, 2024.
Tri-AgencyNSERC: Idea to Innovation (I2I) GrantMarket assessment ($15,000), Phase I ($125,000), Phase Ib ($60,000), Phase IIa ($125,000), Phase IIb ($350,000).This opportunity aims to accelerate the pre-competitive development of promising technology originating from the university and college sector, and promote its transfer to a new or established Canadian company. I2I grants provide funding to college and university faculty members to support research and development projects with recognized technology transfer potential. This is achieved through defined phases by providing crucial assistance in the early stages of technology validation and market connection.April 2, 2024; June 25, 2024; September 16, 2024.
Tri-AgencyCIHR Team Grant: HIV/AIDS and STBBI Community-Based Research Team GrantsLOI Stage: Up to $100,000 for 1 year.
Full Application Stage: Up to $200,000 per year for up to 5 years
The purpose of the funding opportunity is to support a diversity of CBR teams to build and strengthen capacity for CBR and knowledge mobilization activities that are centred in the self-determined priorities of the communities and will lead to improved health outcomes for key populations disproportionately affected by STBBI in Canada. Funds will be made available in two stages: Letter of Intent (LOI) stage to support building community-centred teams and developing full applications; and Full Application Stage for applicants successful at the LOI stage.
The objectives the CBR Team Grants are to:
• Strengthen and build capacity within communities for CBR and KM that delivers impactful, useful, and timely results for populations at greatest risk of STBBI in Canada;
• Advance community-centred approaches to STBBI research by establishing meaningful partnerships between communities and researchers from academic or other research institutions; and
• Improve health equity by conducting, enabling and/or facilitating access to research that addresses structural, social, behavioural and biomedical determinants of health for key populations affected by STBBI.
CIHR will be hosting webinars to inform participants about the requirements of this funding opportunity on Thursday, February 8, 2024, at 1:30 PM ET; Wednesday, February 14, 2024, at 3:00 PM ET; and May 2024 (details to follow; see webinars.)
Letter of intent: June 13, 2024.
Full application: September 4, 2025.
Tri-AgencyNSERC Alliance Grants$20,000 to $1 million per year for 1-5 yearsSupport university researchers to collaborate with partner organizations, which can be from the private, public or not-for-profit sectors.
NOTE: All NSERC grant applications must be submitted through the University of Toronto Research Services Office.
No Deadline
Tri-AgencyNSERC Alliance InternationalCatalyst Grants: $25,000 for 1 year.
Collaboration Grants: Up to $100,000 per year for up to 3 years.
These are for Canadian university researchers working in the natural sciences and engineering in partnership with international collaborators from the academic sector. The overall objectives are to: 1) allow Canadian researchers to initiate the development of international collaborations; and 2) provide support for Canadian researchers participating in international collaborative projects of global importance and benefit to Canada. The applicant and any Canadian co-applicants must have an active NSERC peer-reviewed grant, as primary applicant, at the time of application.
NOTE: All NSERC grant applications must be submitted through the University of Toronto Research Services Office.
No Deadline
Other CanadianCall for Tier 1 CIHR Canada Research Chair--Unity Health is pleased to have an open call for Tier 1 CIHR Canada Research Chair. This call is open to individuals who self-identify as women or a gender minority (transgender, gender-fluid, non-binary, Two-Spirit). Please contact Erica Conte at Erica.Conte@unityhealth.to if you have any questions about this opportunity.February 22, 2024.
Other CanadianLung Cancer Canada: Lung Ambition AwardsUp to $50,000 This grant program is open to all Canadian clinicians and researchers (across the multi-disciplinary spectrum) who work in the lung cancer space. It supports research in lung cancer within the following areas:
• Enhancing early detection – including research into methodologies like screening, incidental pulmonary nodules and blood-based testing, particularly for those individuals not meeting current screening criteria
• Improving the timeliness and/or coordination of care – including ways in which institutions or health care systems can improve care along the patient pathway
• Addressing disparities to improve equity – including identification of systemic barriers and ways to overcome them
February 29, 2024.
Other CanadianModerna Canada Fellowship Program 2024Up to USD $75,000 per year to support salary costs and up to USD $100,000 per year for expenses. Term between 1-2 years.The fellowship program aims to support novel research in the field of mRNA Science, with a specific focus on Moderna’s areas of interest: General mRNA (platform, LNP, etc), COVID-19, Respiratory Syncytial Virus (RSV), Influenza, Epstein-Barr Virus (EBV), Cytomegalovirus (CMV), Norovirus, Lyme, Group A Streptococcal (GAS), Pertussis, ESKAPE Pathogens, Delivery mechanisms by RNA to tissues/organs affected by rare genetic disorders (excluding lung and liver).February 29, 2024.
Other CanadianThe Ontario Ministry of Transportation (MTO): Road Safety Research Partnership Program (RSRPP)Up to $50,000 per year for 1-3 yearsThis program provides funding to a network of provincial and regional non-profit organizations with road safety mandates. The program supports public awareness initiatives that address priority issues such as, aggressive driving, pedestrian safety, distracted driving, impaired driving, and cycling safety. February 29, 2024.
Other CanadianFighting Blindness Canada: Early Career Research Grant in Retinal Degenerationup to $200,000 for 2 years. This opportunity will support exceptional early career researchers (i.e., within 7 years from the start of their first independent academic appointment) with interest in retinal (including optic nerve) degeneration. The competition is open to all research related to retinal degeneration but may prioritize funding projects with potential to impact individuals with inherited retinal diseases (e.g. retinitis pigmentosa, Usher syndrome, choroideremia), age-related macular degeneration, diabetic retinopathy or glaucoma.Letter of intent: March 7, 2024.
Full application: April 25, 2024.
Other CanadianU of T The Faculty of Applied Science and Engineering (FASE): Joint EMHSeed and XSeed Funding Program$60,000 CAD per year for 2 yearThis program aims to catalyze new innovative partnerships between researchers from FASE and researchers from their partner divisions, including the Temerty Faculty of Medicine (TFoM). Funding is available for up to 2 collaborative projects with TFoM through the EMHSeed program.
If you wish to apply, please contact VPRI@unityhealth.to by February 21 as matching funds will be limited.
March 11, 2024.
Other CanadianSarah McComb Award for Cancer Research$150,000 This is an internal funding opportunity that will provide $150,000 to support a cancer-related project being conducted primarily at St. Michael's Hospital or Providence Healthcare. To be considered for this funding please submit an Expression of Interest (EOI) by Friday, March 15th. To request an EOI form please email VPRI@unityhealth.to. EOI: March 15, 2024
Other CanadianU of T Emerging and Pandemic Infections Consortium (EPIC): Various Opportunities$50,000 for one yearIgnite Grants: Formerly named Proof-of-Principle Grants, Ignite Grants provide seed funding to support early stage and pilot level projects that show promise in developing novel understanding or innovations in the area of infectious disease and/or pandemic preparedness. March 18, 2024.
$120,000 over two yearsConvergence Postdoctoral Fellowships: These fellowships support post-doctoral trainees who are driving innovative infectious disease-focused projects that bridge two research disciplines. These senior trainees are expected to engage faculty from at least two different departments and/or divisions, with formal co-supervision by each.March 25, 2024.
$120,000 over two yearsCareer Transition Awards: These awards support senior trainees who are ready to lead an independent project. The funding is intended to facilitate an achievable, small-scale project led entirely by the applicant, while being mentored by their supervisor and a dedicated mentor in the EPIC community.April 1, 2024.
Other Canadian2024 Call for Angels Den Applications--The 2024 Call for Angels Den Applications has launched! This year, we celebrate the 10th Anniversary of Angels Den, so we are increasing our main prizes to $250,000 each and will be giving out a total of $700,000 in research funding. In addition to fostering brand new research projects in medical discovery and health system innovation, we will be showcasing 10 years of the impact that donors and sponsors have had through their support of our researchers. The Office of the Vice President, Research & Innovation and St. Michael’s Foundation prioritize scientific excellence, translation, commercialization and impact. We invite your submission for the 2024 competition.
For a copy of the call for proposal or the application please email VPRI@unityhealth.to.
March 25, 2024.
Other CanadianThe University of Toronto Emerging and Pandemic Infections Consortium (EPIC) – New Connections Grants$100,000 for 2 yearsThe U of T EPIC New Connections Grants support innovative projects that are fostered through cross-disciplinary collaboration across at least two research groups. Successful proposals will feature joint lead investigators with clearly distinct expertise from different university divisions and/or EPIC partner institutions coming together for their first significant research collaboration. The joint investigators will tackle an infectious disease research question by applying innovative methodologies that capitalize on their different areas of expertise for impactful outcomes.  March 27, 2024.
Other CanadianThe Novo Nordisk Network for Health Populations (NHP): 2024 Network Catalyst Grant CompetitionUp to $100,000 for one year.The Novo Nordisk NHP is committed to supporting multi-disciplinary, collaborative teams to co-design projects that will support the development of interventions and programs in the Peel Region focused on reducing the burden of diabetes and chronic disease. The NHP will support an evidence-to-practice approach to tailor, adopt, and integrate evidence-informed practices, programs, and policies into local health care, community services, and living environments. Grants will be awarded to support projects that aim to develop, expand, or adapt evidence-informed programs, interventions, or evaluations that align to the Network’s mission: To reduce social inequities in risk and burden of diabetes and other chronic diseases through better care, lower risk factors and healthier living environments. April 1, 2024
Other CanadianInternational Development Research Centre (IDRC) Pre-announcement: addressing neglected areas of sexual and reproductive health and rights in sub-Saharan Africa (ANSRHRA)--Focused on investments to transform service design and delivery and to strengthen the development and implementation of equitable and sustainable movements, ANSRHRA is a new initiative to support gender-transformative implementation research in sub-Saharan Africa. It will contribute to improved sexual and reproductive health and realization of rights while also building systems and structures that enable and support under-served populations, including women and girls, to demand and benefit from the full spectrum of SRHR. The initiative’s overall aim is to support greater realization of neglected SRHR by under-served populations, including women and girls, in sub-Saharan Africa.Letter of intent: April 5, 2024.
Full application (by invitation): September 2024.
Other CanadianJ. P. Bickell Foundation Medical Research GrantRange from $25,000 - $80,000.For medical research, with a focus on innovative basic/translational research projects led by early career researchers. Please note that Unity Health can submit only one application for this grant. To be considered, send a summary of your proposed project/program (maximum 1 page) to VPRI@unityhealth.to by March 22, 2024.Sponsor Deadline: April 30, 2024.
Other CanadianSigma/Canadian Nurses Foundation GrantUp to USD $5,000.This supports research that advances the practice of nursing with an emphasis on nursing care issues. Nursing care research or clinical nursing research is defined as research that is practice-based or that will provide the groundwork for future practice-based research studies. Research funded through this grant must provide evidence that there is a potential impact on nursing practice, whether direct or indirect. Given the recent global COVID-19 pandemic, research that explores issues that impact nursing practice are welcomed. In addition, projects that focus on marginalized populations are strongly encouraged and will be given preference, other qualifications being equal.December 1, 2024.
Other CanadianMultiple Sclerosis Society of Canada: Contract Research Organization (CRO) GrantUp to $100,000 to pay for CRO services for up to a 1 year term.This will enable principal investigators to apply for funding to pay for specific research services offered by CROs and specialized drug discovery and development organizations, with the aim of advancing research and development of treatments for progressive MS.Open competition with no set deadline.
Other CanadianGrand Challenges Canada: Transition To Scale (TTS) Request for ProposalsRange from $250,000 to $3M for 6 months up to 2 yearsThis seeks to support the transition to scale and sustainability of Bold Ideas with Big Impact in Global Health. It supports promising innovations with a proven impact that have the potential to save or improve lives. Applications are invited in the following areas: Maternal and Newborn Health, Digital Health, Medical Products and Technology, Community Health Worker Models, Urban Sanitation & Hygiene, and Options. Applicants must be either a non-profit organization, for-profit company, research/academic institution, or another recognized institution that is incorporated in a low- or middle- income country, with a current priority in Sub-Saharan Africa.Concept notes accepted on a rolling basis
Other CanadianUniversity of Toronto Institutional Strategic Initiatives (ISI)From $50,000-$300,000 per year for up to 3 years.ISI awards are intended to establish research capacity in high-priority areas, with the goal of realizing transformational impacts on issues of societal importance. Proposed investigator-initiated initiatives must meet the following key criteria: 1) Address a significant challenge and associated research questions that requires an interdisciplinary approach; 2) Matching funds secured from three or more Academic Divisions; 3) Path to sustainability demonstrated by a clear opportunity for external funding. Ongoing
Other CanadianCollaboration Opportunities: National Research Council Canada (NRC) Challenge Programs--The NRC offers potential opportunities for collaboration in the following areas:
• Aging in Place
• Artificial Intelligence for Design
• Disruptive Technology Solutions for Cell and Gene Therapy
• High-throughput and Secure Networks
• Pandemic Response
Potential collaborators can register their interest to work with NRC on the Challenge Programs website.
Ongoing
Other CanadianRare Diseases: Models & Mechanisms Network Catalyst Grants$25,000 The Rare Diseases: Models & Mechanisms Network has been established to catalyze connections between people discovering new genes in patients with rare diseases, and basic scientists who can analyze equivalent genes and pathways in model organisms. Catalyst Grants fund projects that will allow rapid confirmation of potentially disease-causing genes, and fuel pilot studies to improve understanding of how specific gene mutations cause disease. This application is intended for investigators who wish to link their gene discovery to a model organism researcher.Continuous
Other CanadianPhysicians' Services Incorporated (PSI) Foundation: Health Research Grant & New Investigator GrantHealth Research Grant: Up to $250,000 for 3 years.
New Investigator Grant: Up to $300,000 for 3 years.
Areas of Support: clinical research, medical education research, health systems research. Applicant must be a College of Physicians and Surgeons of Ontario licensed MD. New Investigators must be within five years of their first academic appointment. Rolling deadline
Other CanadianAlberta Gambling Research Institute (AGRI): Various OpportunitiesLeveraging Grants: Up to $80,000.
• Team Development Grants: Up to $10,000 for up to 18 months.
Small Grants: Up to $10,000 for up to 1 year.
Leveraging Grants: To enable researchers, with non-AGRI funding to augment projects with a gambling-related component.
Team Development Grants: To support the development of multi/interdisciplinary teams of academic researchers, among Partner Universities, nationally, internationally, and other stakeholders in order to establish research programs.
Small Grants: To support small developmental initiatives typically intended to lead to major grant applications.
NOTE: For AGRI grants, the applicant must be one of the principal investigators and have grant-holding status at the University of Alberta, Calgary, or Lethbridge. Research collaborators may come from other institutions.
• Leveraging Grants: Rolling call.
• Team Development Grants: Rolling call.
• Small Grants: October 1st and May 1st each year.
Other CanadianTelus FundsVariousFor entertaining and engaging web series with the potential to positively impact families and friends providing care for loved ones struggling with a health condition.Various
Other CanadianOntario Centre of Innovation (OCI) Voucher for Innovation and Productivity (VIP) ProgramMinimum of $20,000 up to a maximum of $150,000 per year towards the direct costs of research (Industry Partner contribution has to be minimum of 1:1 cash match to the OCE contribution, where at least 50% must be spent at the post-secondary institution.)This program helps companies develop, implement and commercialize technical innovations by supporting partnerships between Ontario's industry and publicly funded post-secondary institutions and research hospitals. VIP projects are intended to generate economic benefit for companies in Ontario (including job creation/retention, new revenue generation, investment attraction, cost savings, value chain development), in the short-to-medium term (e.g. within three years of project completion).

If you are interested, please contact Samar Saneinejad (Samar.Saneinejad@unityhealth.to).
No Deadline
InternationalInternational Society for the Study of the Lumbar Spine (ISSLS): Clinical Science Research GrantUSD $20,000.The purpose is to promote research into the lumbar spine. The research proposal should be in clinical science and at least one investigator must be an ISSLS member.February 28, 2024.
International Alzheimer's Association (ALZ): Various OpportunitiesUp to USD $200,000 (direct and indirect costs) for up to 3 years. Alzheimer's Association Research Grant (AARG) / Alzheimer's Association Research Grant to Promote Diversity (AARG-D): This provides newly independent investigators with funding that will allow them to develop preliminary or pilot data, to test procedures and to develop hypotheses. The intent is to support early-career development that will lay the groundwork for future research grant applications to federal or other funding entities. Applicants must be an Assistant Professor or Associate Professor at their respective academic institution and less than 18 years past their doctoral degree or post-residency (M.D. or D.O.). For the AARG-D, eligible applicants have the same requirements as the AARG program, but are an underrepresented faculty in biomedical and behavioral research on a national, international or institutional basis. Letter of Intent: February 28, 2024; Application (by invitation): May 1, 2024.
Up to USD $200,000 (direct and indirect costs) for up to 3 years. Alzheimer's Association Research Grant-New to the Field (AARG-NTF) / Alzheimer's Association Research Grant to Promote Diversity-New to the Field (AARG-D-NTF): The goal of the New to the Field program is to provide an opportunity for investigators with expertise outside neurodegenerative research to apply their expertise to advance and accelerate Alzheimer’s and all other dementia. Applicants must be an Assistant Professors or above at their respective academic institution and are new to the field of neuroscience or neurodegeneration. For the AARG-D-NTF, eligible applicants have the same requirements as the AARG program, but are an underrepresented faculty in biomedical and behavioral research on a national, international or institutional basis.
InternationalThe Glaucoma Foundation (TGF): Exfoliation Syndrome, Exfoliation Glaucoma and Intraocular Pressure-Independent Mechanisms of Optic Nerve Degeneration in GlaucomaUp to USD $60,000 for 1 year.Examples of research that may be considered range from basic science to clinical interventions, such as genetics and genomic medicine, disease modeling, assessment of ocular perfusion, artificial intelligence, and clinical research.March 1, 2024.
International The American Association for the Surgery of Trauma (AAST): Research Scholarship$50,000. Study must be completed within 2 yearsThis is to solicit research applications from early-career investigators proposing basic science, translational, or clinical studies to advance trauma, surgical critical care, emergency general surgery care and health equity research. Pilot projects seeking exclusively preliminary data, or “proof of concept” projects will only be considered if the applicant provides a sound scientific foundation for the proposal. Projects centered on Global Surgery/Trauma will only be considered if they are found to be of sufficient merit and are scientifically sound.
To be eligible to apply, you must hold a faculty appointment at the level of instructor or assistant professor, be AAST member (either Fellow or Associate) or have submitted an application for Associate membership in the AAST, and you must be an Early Career investigator who has not yet achieved governmental, large foundational, or endowed grant funding as a Principal Investigator.
March 1, 2024.
InternationalSociety for Vascular Surgery (SVS) Clinical Research Seed GrantUSD $25,000 for 1 year.This program has the following goals:
• Encourage the interest and development of clinical investigators among the SVS membership, particularly junior members or those with limited prior experience as Principal Investigators
• Provide direct support for pilot clinical projects that have potential to develop into larger studies fundable by industry or governmental sources
The PI must be 1) an SVS Active Member within the first 10 years of practice or 2) an SVS Early Active Member - a fellowship- or integrated residency-trained, board-eligible, vascular surgeon within the first 10 years of practice with a full-time faculty position with an SVS Active Member serving as mentor.
March 1, 2024.
International Lung Cancer Research Foundation (LCRF): Various Opportunities $2,500,000 for 4 years.Team Science Award (TSA) on Advancing Therapies Towards Curing Oncogene-Driven Lung Cancers: With the International Association for the Study of Lung Cancer (IASLC), LCRF encourages applications on a wide variety of topics related to oncogene-driven lung cancer. Proposals will address important mechanistic questions and developmental therapeutics across the care continuum and have the immediate potential to increase survivorship. A clinical trial must either be initially incorporated into the project or be an immediate result of the outcome of the research. Letter of Intent: March 4, 2024;
Full proposal (by invitation): August 12, 2024.
$150,000 for 2 years.LCRF Leading Edge Research Grant Program: This is to fund innovative projects across the full spectrum of basic, translational, clinical, epidemiological, health services, early detection, disparities, and social determinants of health research. Letter of Intent: March 4, 2024;
Full proposal (by invitation): June 10, 2024.
$150,000 for 2 yearsMinority Career Development Award (CDA) in Lung Cancer: This is to provide funding to minority postdoctoral/clinical fellows and assistant professors within 10 years of completing their MD and/or PhD degrees to submit proposals. Investigators must be from racial or ethnic groups that are underrepresented in health-related sciences and biomedical research.Letter of Intent: March 4, 2024;
Full proposal (by invitation): June 10, 2024.
$150,000 for 2 years Research Grant on Early Detection and Pre-Neoplasia in Lung Cancer: This is focused on identifying, characterizing, and developing approaches and techniques that will allow early detection and/or risk reduction of lung cancer and gaining insight into pre-neoplastic processes in the lungs. The program is designed to support early-stage researchers and faculty within the first 10 years of their faculty appointment.Letter of Intent: March 4, 2024;
Full proposal (by invitation): June 10, 2024.
$150,000 for 2 years Research Grants on Understanding Resistance in Lung Cancer: This focuses on understanding the development, prevention, and therapy of resistance by supporting research projects that are identifying, characterizing, treating, or preventing resistance to therapies in lung tumor cells, tissues, mouse models, and/or patients. This opportunity is designed to support post-doctoral researchers, clinical fellows, or investigators with less than 10 years of experience since their initial faculty appointment.Letter of Intent: March 4, 2024;
Full proposal (by invitation): June 10, 2024.
InternationalAmerican Psychological Foundation (APF): Various Opportunities

NOTE: The list includes those grants valued more than USD $10,000. Please see the APF website for other opportunities valued at or less than USD $10,000.
USD $50,000. Esther Katz Rosen Fund Grants: Support will be provided for activities on the advancement and application of knowledge related to identified gifted and talented children and adolescents. March 6, 2024.
USD $20,000Visionary Grants: Support research, education and intervention projects and programs that use psychology to solve social problems in the priority areas listed on the opportunity website. Applicants must be a graduate student or early career researcher (no more than 10 years postdoctoral). April 3, 2024.
USD $22,500Walter Katkovsky Research Grants: Support research on the general topic of psychotherapy. Applicants must: be psychologists up to 12 years of postdoctoral. April 17, 2024.
USD $22,000. John and Polly Sparks Early Career Grant for Psychologists Investigating Serious Emotional Disturbance (SED): Supports early career psychologists conducting research in the area of early intervention and treatment for serious emotional disturbance in children. Applicants must be early career psychologists (no more than 10 years postdoctoral. April 24, 2024.
USD $15,000. F.J. McGuigan Early Career Investigator Research Grant on Understanding the Human Mind: To recognize and support the efforts of an early career psychological scientist who is pursuing research that aims to address any aspect of mental function (e.g., cognition, affect, motivation) and seeks to understand the mind from both a behavioral and neural perspective.June 5, 2024.
Up to USD $15,000. Wayne F. Placek Grants: Encourages research to increase the general public’s understanding of homosexuality and sexual orientation, and to alleviate the stress that lesbian women, gay men, bisexual women, bisexual men, and transgender individuals experience in this and future civilizations. June 12, 2024.
Up to USD $21,000. The Springfield Research Fund Grants: Supports research of contemporary LGBTQIA+ issues in an effort to dispel stereotypes and other negative information that leads to prejudice and discrimination. Applicants must be early career psychologists no more than 10 years postdoctoral. June 12, 2024.
Up to USD $20,000. Marian R. Stuart Grant: To further the research, practice, or education of an early career psychologist on the connection between mental and physical health, particularly for work that contributes to public health. Applicants must be early career psychologists no more than 10 years postdoctoral. July 10, 2024.
Up to USD $10,000. Division 39 Marsha D. McCary Fund Grant for Psychoanalysis: This encourages and supports programs in education, research, and service that will advance the profession and keep the psychological community and the public informed of developments in psychoanalytic scholarship, research, and practice.August 31, 2024.
USD $19,000.Bruce and Jane Walsh Grant in Memory of John Holland: Supports scientific, scholarly, or applied research and/or educational activities investigating how personality, culture, and environment influence work behavior and health (mental and physical). Applicants must be a graduate student or early career researcher (no more than 10 years postdoctoral). September 18, 2024.
Up to USD $34,000.John and Polly Sparks Grant for Rural First-Responders Mental Health Interventions: This will fund the research of psychologists for evidence-based research and intervention in providing mental health training dissemination to first responders in rural areas.October 23, 2024.
InternationalSociety for Pediatric Radiology (SPR) Research and Education Foundation: Two Opportunities

For the 2024 grant cycle, the SPR Research and Education Foundation Board strongly encourages submissions focused on health policy or health services research.
Up to $50,000 for 18 monthsEducation Project Grant: This is to provide support for pediatric radiology education projects. Projects should focus on education and learning related to unique aspects of imaging or image-guided therapy/intervention in children, promote the importance of imaging or imaging expertise in improving health care in children, cultivate multidisciplinary cooperation, and provide opportunities for additional funding. Priority will be given to projects that lead to the creation of enduring web-based or electronic resources to improve teaching and learning of pediatric radiology and which can be disseminated without charge to SPR members and via the World Federation of Pediatric Imaging. The project leader must be a member of the Society for Pediatric Radiology and holds a full-time faculty position in an educational institution at the time the award commences. March 8, 2024.
Up to $100,000 for 18 monthsMulti-Institutional Pilot Grant: This is to fund collaborative projects across multiple institutions to increase the sample size of rare pediatric diseases to allow for more rigorous, reproducible research in the pediatric population. The Grant is provided to facilitate projects that require (1) recruitment of patients from multiple institutions to achieve a necessary study population and/or (2) equipment and physical resources from multiple institutions.
International Jeffrey Modell Foundation: Research Grants

This program support research for Primary Immunodeficiencies through grant opportunities that provide funding to advance science and save lives.
up to USD $250,000 for 2 yearsTranslational Research Program: supports innovative and novel investigations in Primary Immunodeficiency (PI) focusing on translational research leading to meaningful clinical application. Letter of Intent: March 13, 2024;
Full Application: July 8, 2024.
up to USD $50,000 for 2 yearsSpecific Defect Research Program: supports research that studies the mechanisms and presentation of specific defects of the immune system to gain a better understanding of the defects and their impact on overall health outcomes. Applications are accepted and reviewed on a rolling basis, so you may apply at any time.
up to USD $25,000 for 2 yearsC.H.I.L.D.R.E.N!®: supports research focused on children living with PI throughout the world, while addressing healthcare disparities, especially in developing countries, through education, testing, diagnosis, and treatment.Applications are accepted and reviewed on a rolling basis, so you may apply at any time.
International Brain & Behavior Research Foundation (BBRF) NARSAD Young Investigator (YI) GrantsUp to USD $35,000 per year for up to 2 years.The goal of the YI program is to help researchers launch careers in neuroscience and psychiatry and gather pilot data to apply for larger federal and university grants. The YI Grant supports advanced post-doctoral fellows, instructors and assistant professors (or equivalent). Investigators at the rank of associate professor or equivalent are not eligible. Applicants may only apply twice for an initial YI Grant.March 12, 2024.
International Mark Foundation for Cancer Research: Endeavor AwardsUSD $3,000,000 disbursed over a 3-year term.These support collaborative research projects that bring together investigators with diverse areas of expertise to tackle challenges in the prevention, diagnosis, and treatment of cancer. These grants are awarded to teams of three or more investigators to generate and integrate data from diverse lines of research and transform those insights into advances for cancer patients that could not be achieved by individual efforts.Letter of Intent: March 12, 2024;
Application (by invitation): TBA.
InternationalCenter of Excellence for Influenza Research and Response (CEIRR): Pilot Research Program$600,000 for 2 yearsThis program aims to connect investigators not currently part of CEIRR with one of the existing CEIRR Centers. Research concepts should advance the mission of NIAID and broadly be focused on topics relevant to NIAID’s Universal Influenza Strategic Plan for pandemic preparedness. Research at the CEIRR centers focuses on the study of influenza at the interspecies interface and strongly emphasizes the study of influenza in humans. Overall, CEIRR research projects include cohort studies and human and animal sampling to further understand influenza infection, transmission and vaccination; identify immunological factors that determine disease outcome in the response to influenza infection and vaccination; and studies to determine how influenza viruses evolve, adapt and transmit between humans and at interspecies interfaces.March 14, 2024.
InternationalSurgical Robot Challenge 2024--This global competition draws participation from top surgical robotics groups worldwide, providing a platform to unveil inventive concepts across various surgical robot platforms. While applications are open to diverse focus areas, submissions should highlight innovation, practical application, and thoughtful design in showcasing how robots can enhance surgical procedures. The ultimate goal is to contribute to quicker recovery times, smaller scars, reduced blood loss, diminished pain, earlier return to work, and shorter hospital stays.March 22, 2024.
International Radiological Society of North America (RSNA) Emerging Issues Grant USD $100,000 for 1 year.This grant was developed to rapidly and effectively address urgent issues that threaten the health and well-being of disparate populations. It will provide support for research related to:
1) Environmental impact/sustainability of radiology; or,
2) Value based radiology and its impact on patient care in today's resource constrained health care environment.
Applicants must be an RSNA member the time of application and throughout the duration of the award.
March 22, 2024.
International The ZOLL Foundation: Early-stage research fundingTypically in the $10,000 - $50,000 rangeThe ZOLL Foundation provides grants, often seed funding, to young investigators conducting research that improves care for patients suffering from serious cardiopulmonary and respiratory conditions. All applications must include a mentor that will provide both a reference as well as ongoing guidance and support to the researcher.March 31, 2024; June 03, 2024.
International Centers for Disease Control: Sexually Transmitted Infection Surveillance Network (SSuN) Cycle 5--The purpose of this opportunity is to support sentinel and enhanced surveillance for STIs providing complete demographics, behavioral risk, clinical and preventive services data missing in routine reporting. This opportunity will supports two core strategies for (A) sentinel surveillance in STI/sexual health clinical facilities, and (B) enhanced case-based surveillance in community settings and one supplemental strategy (Strategy C) for special surveillance projects of national or local interest. Both core strategies integrate a syndemic approach to monitoring STIs, HIV, behavioral data, and on preventive services accessed by all persons presenting for care in sexual health settings, and persons diagnosed and reported with selected STIs from all provider settings in defined geographic areas. Letter of intent: April 1, 2024
Final: May 15, 2024.
InternationalThe International Center for Responsible Gaming (ICRG)Up to $172,500 for up to 2 yearsLarge Grant For Research On Gambling Disorder And Responsible Gambling: The ICRG seeks proposals of high scientific merit from investigators who show promise of disseminating their work at high-impact conferences and in peer-reviewed scientific journals. This is to support research investigations of gambling disorder and responsible gambling. Letters of Intent: April 1, 2024;
Full Application: July 15, 2024.
Up to $40,000 for 1 yearSeed Grant For Research On Gambling Disorder And Responsible Gambling: This is to support a variety of research activities, exploring the etiology, prevention and treatment of gambling disorder, and the development and evaluation of responsible gambling strategies, such as: Pilot and feasibility studies, Secondary analysis of existing data, Small, self-contained research projects, Development of research methodology, Development of new research technology. The ICRG encourages early career investigators to apply for a Seed Grant.May 1, 2024.
International Worldwide Cancer Research: Project GrantsUp to GBP £275,000 for 12 to 36 months.These support research that seeks to answer the difficult questions in cancer biology, including basic, fundamental or translational research into the prevention, diagnosis or treatment of cancer. These grants do not support clinical research, including clinical trials, patient care, nursing or healthcare delivery research; nor other types of applied cancer research such as policy, public health or psychosocial research. The principal investigator on the application must be a suitably qualified researcher (minimum of PhD followed by three years research experience, or equivalent qualification or research experience).April 2, 2024.
InternationalCystic Fibrosis Foundation (CFF): Clinical Research AwardUp to USD $150,000/year for 3 years for single-center clinical research awards; Up to $350,000/year for 3 years for multi-center clinical research.This seeks investigator-initiated clinical research projects that have the potential to make an important contribution to the CFF’s mission. Research projects may address diagnosis, treatment, management of disease or symptom, or the pathophysiology of cystic fibrosis using clinical (observational/interventional), translational, or epidemiologic study approaches. Applicants must demonstrate access to sufficient numbers of CF patients and appropriate controls.Letter of Intent: April 4, 2024.
Full Application: August 13, 2024.
InternationalCystic Fibrosis Foundation (CFF): Multiple Principal Investigator Clinical AwardUp to $200,000/year for up to 3 years.This is to provide support for multi-investigator-initiated clinical research projects that have the potential to make an important contribution to the Cystic Fibrosis Foundation’s mission to cure CF and to provide people with CF the opportunity to lead long lives. At least two — but no more than three — investigators may be associated with a project. Applicants must be independent investigators. Research projects may be designed to test new hypotheses and/or new methods (pilot and feasibility) or to advance established results with the potential to address diagnosis, treatment, management of disease or symptoms, or the pathophysiology of cystic fibrosis using clinical (observational/interventional), translational, or epidemiologic study approaches.Letter of Intent: April 4, 2024.
Full application: August 13, 2024.
InternationalCenters for Disease Control: NCHHSTP Epidemiologic and Economic Modeling for HIV, Viral Hepatitis, STD, and TB--This funding opportunity will support modeling of disease dynamics and advanced data analytics to inform and improve HIV, viral hepatitis, STD, TB, and adolescent health interventions and programs. This announcement will build on the success of prior modeling efforts by continuing to enhance existing models that guide informed decision-making, provide tools and data for prioritizing public interventions and programs, and to guide the allocation of scarce program resources. The cooperative agreement will also expand the use of advanced data analytics using predictive models, machine learning and artificial intelligence, as well as allow for the development and implementation of research based on these modeling and advanced data analytic projects in alignment with NCHHSTP-related public health priorities. Letter of intent: Recommended but not required.
Final: April 8, 2024.
International American Association for Cancer Research (AACR): Various OpportunitiesUSD $50,000.AACR-KidneyCAN Kidney Cancer Innovation and Discovery Grants: This new grant mechanism seeks to stimulate creative approaches to translate basic research into new treatment options for kidney cancer. April 11, 2024.
USD $130,000 for 2 years.AACR-Exelixis Renal Cell Carcinoma Research Fellowship: This encourages and supports a postdoctoral or clinical research fellow to conduct renal cell carcinoma research and to establish a successful career path in this field. The research proposed for funding may be in basic, translational, clinical, or population sciences research and must have direct applicability and relevance to renal cell carcinoma.
International Pfizer: New Appilcation Windows for unsolicited Application for Investigator Sponsored Research (ISR) & General Research

Pfizer has implemented application windows for unsolicited requests.
--Pfizer supports Investigator Sponsored Research (ISR) projects that advance medical and scientific knowledge about our therapies.
An ISR is a type of grant that supports an independent research study where the investigator or organization is the sponsor of the study and where Pfizer provides financial and/or nonfinancial support for the development or refinement of specific and defined medical knowledge relating to a Pfizer asset. This global program is open to all researchers who are interested in conducting their own research. This grant type is used as support for pre-clinical and clinical studies (including interventional and non-interventional), that involve a Pfizer asset (e.g., commercial drug, investigational drug, pure compound).
April 14, 2024; August 25, 2024.
--Pfizer also supports general research projects focused on the development or refinement of specific and defined medical knowledge unrelated to a Pfizer asset.
This grant type is used to support research that does not include the study of a Pfizer asset, including health services research, registry development and/or queries, and outcomes research. This includes observational studies, such as epidemiology studies and certain outcomes research studies where the primary focus is the scientific understanding of disease as well as other types of independent research on disease states.
InternationalGateway for Cancer ResearchTypically in the $200,000 to $1.5 million range for 2-5 years Gateway funds Phase I and II patient-centered cancer clinical trials that have the potential to shift the paradigm for standard of care. Gateway funds treatment-based studies at the bedside, including all types of cancers. Research areas include Biomarkers (prognostic or predictive with supportive treatment), Gene Therapy, Basket Trials, Immunotherapy, and Targeted Therapies. Available Programs:
• Gateway Traditional Grant Program: Core grants funding early phase clinical trials for cancers of all types.
• Integrative Research: This is to support integrative oncology research that pairs conventional therapies with evidence-based, complementary therapies to manage symptoms and side effects from treatment. This also aims to increase quality of life during treatment.
• Society for Integrative Oncology (SIO): Gateway collaborates with SIO to support integrative clinical trials conducted by principal investigators and institutions among its membership. SIO’s mission is to advance evidence-based, comprehensive, integrative healthcare to improve the lives of people affected by cancer.
• Decentralized Clinical Trial Initiative (DCTI): This is to support research leveraging site-less, technology-informed trials, with the objective of bringing clinical trials directly to patients’ doorsteps.
Rolling deadlines 3x per year. Next deadline: April 18, 2024. Anticipated deadlines for 2024: July or August, and November or December.
InternationalCystic Fibrosis Foundation (CFF): Health Equity Team Science AwardUp to USD $200,000 per year for up to 4 years, plus an additional 12% indirect costs per year. The lead institution may request up to USD $50,000 in additional direct costs per year to support an administrative core.A single Health Equity Team must have at least two — and up to four — related research projects (each led by a separate principal investigator with a separate application) that share a well-defined theme and overall objective. The research projects should have the potential to improve our understanding of or have a positive impact on identified barriers to optimal health outcomes for all people with CF related to race and ethnicity, sexual orientation or gender, or socioeconomic status.
NOTE: Applicants must speak with program staff prior to submission to ensure the project design is in line with the goals of this request for application
Letter of Intent: April 23, 2024.
Full Application: September 17, 2024.
International American Psychological Association (APA): Norine Johnson, Ph.D., Psychotherapy Research Grant$15,000 This program awards grants to early career psychologists (ECPs; within 10 years post earning the doctoral degree) for research on psychotherapy. All aspects of psychotherapy research can be supported, including the psychotherapy relationship, psychotherapy process, or psychotherapy outcomes. May 1, 2024.
International Foundation for Physical Medicine & Rehabilitation (Foundation for PM&R): Various OpportunitiesUSD $20,000 for one year.Encompass Midcareer Investigator Research Grant: For research in topics related to the field of physical medicine and rehabilitation; it is to be used as seed money for new research projects that extend an established investigator’s work in new directions. Preference will be given to projects that address the topics in our Research Priorities (Chronic Pain, Musculoskeletal, Stroke, Traumatic Brain Injury). Eligible applicants for grant include any physiatrist or faculty member in a division or department of physical medicine and rehabilitation who is at least 5 and not more than 20 years post-completion of a terminal degree and subsequent training program. At least one member of the research team (PI or co-investigator) must be a member of the American Academy of PM&R (AAPM&R) and/or the Association of Academic Physiatrists (AAP).May 1, 2024.
USD $30,000.Scott Nadler PASSOR Musculoskeletal Research Grant: This is a seed grant for research in topics related to musculoskeletal rehabilitation in the field of physical medicine and rehabilitation. Applicant and/or at least one co-investigator must be members of the AAPM&R and/or the AAP.
USD $10,000.Pain Management and Spine Care Research Grant: This is a seed grant for research in topics related to pain medicine and spine care in the field of physical medicine and rehabilitation. Applicant and/or at least one co-investigator must be members of the AAPM&R and/or the AAP.
InternationalCystic Fibrosis Foundation (CFF): Path to a Cure (PTAC) – Various OpportunitiesUp to USD $150,000/year for up to 3 years.PTAC Research Grant: This is intended to facilitate or enable the development of new information that may contribute to the development of new therapies for CF, especially projects focused on advancing CFTR repair and replacement strategies. May 2, 2024.
Up to USD $50,000/year for up to 2 years. PTAC Pilot and Feasibility Award: This is to support projects that will develop and test new hypotheses and/or new methods that could eventually contribute to the development of a cure for CF, and to support promising new investigators as they establish themselves in research
InternationalAmerican Academy of Pediatrics (AAP): Neonatal Resuscitation Program (NRP) Grant Applications: Multiple Opportunities)Up to $15,000 for one year.Human Factors or Education Grant: Any health care professional with an interest in the impact of human factors on delivery room resuscitation or optimization of NRP education. Intent of Application: May 3, 2024.
Full Application: August 2, 2024.
Up to $15,000 for one yearNRP Young Investigator Award: Physicians-in-training or individuals within 4 years of medical training.
Up to $50,000 for one year.NRP Research Grant Program: Any health care professional with an interest in neonatal resuscitation.
InternationalPre-Announcement: Ninth Global Alliance for Chronic Diseases (GACD) Call: Implementation research for management of multiple long-term conditions in the context of non-communicable diseases (NCD)--This call focuses on implementation research proposals, to address management of multiple long-term conditions, in the context of non-communicable diseases (NCDs). Proposals should aim to improve the availability of effective, equitable, efficient, integrated, patient-centered, safe, and timely care for people living with multiple long-term conditions (including at least one non-communicable disease), in low- and middle-income countries or among disadvantaged populations in high-income countries. Applicants are strongly encouraged to bring together teams across disciplines and sectors and must show evidence of collaboration with communities and decision makers, such as policymakers or health system leaders.Call Launch: January 2024.
First stage proposals: May 15, 2024.
Second stage proposals (by invitation): September 18, 2024.
International Oncology Nursing Society (ONS) Foundation: Various OpportunitiesUSD $50,000. RE03 General Topic Research Grant: This will support rigorous scientific oncology nursing research conducted by emerging to mid-career oncology nurse researchers who have not previously received and completed at least one research study with a funding level of $50,000 as the study principal investigator (PI). Letters of intent: May 16, 2024.
Full proposal: June 28, 2024.
USD $100,000.RE33 General Topic Research Grant: This will support rigorous scientific oncology nursing research, including investigator-initiated research, pilot or feasibility studies, supplements to currently funded projects, or developing a new aspect of a program of research.
USD $100,000.Focused Research Grant – Oral Chemotherapy Adherence: This will support rigorous scientific oncology nursing research projects that address oral chemotherapy adherence.
InternationalAmerican Society for Laser Medicine and Surgery (ASLMS) Research Grants

NOTE: To be eligible for ASLMS grants, all non-ASLMS members will be required to apply for and be accepted into ASLMS membership.
Up to USD $65,000 for 1 year. A. Ward Ford Memorial Research Grant: For direct clinical or basic science research investigating current use or potential new applications of laser or other light based therapy. Priority will be given to applicants who are interested in or entering an academic teaching or research position, but all applications will be considered. June 1, 2024.
International Intuitive Foundation Clinical Research Grants for Robotic-Assisted SurgeryUp to USD $75,000 per project.These grants support clinical research at non-profit institutions worldwide focused on the field of robotic-assisted surgery. Successful proposals will study important questions related to surgical care and patient outcomes.Letter of Intent: June 7, 2024.
Full Proposal (by invitation): August 30, 2024.
InternationalRadala Foundation- Advanced Research Grants in ALS200,000 CHF for 2 years.The Radala Foundation is looking for established, leading principal investigators eligible for research funding to pursue a potentially ground-breaking, high-risk project for 2 years in basic research in ALS.
Principal Investigators (PI) - are expected to be active researchers who have a track-record of significant research achievements in the last 10 years. Investigators active in ALS research or in broadly related fields are encouraged to submit proposals relevant to ALS.
June 30, 2024.
InternationalSigma Theta Tau International Honor Society of Nursing: Various OpportunitiesUSD $20,000. Sigma/American Nurses Credentialing Center Evidence-Based Practice Implementation Grant: This opportunity encourages nurses in clinical settings to apply evidence to practice and evaluate the effects on patient outcomes. The grant will be evaluated and awarded based on the quality of the proposal which includes: background and significance; problem statement including EBP model; evidence synthesis providing support for proposed intervention; goals with time frame; estimated magnitude for improvement to patient care and outcomes; implementation strategy; evaluation plan for implementation and outcomes; budget.July 1, 2024.
USD $5,000. Sigma/Doris Bloch Research Award: This award encourages nurses to contribute to the advancement of nursing through research. Allocation of funds is based on the quality of the proposed research, the future promise of the applicant and the applicant's research budget. Applications from novice researchers who have received no other national research funds are encouraged and will receive preference for funding, other aspects being equal.
InternationalE.W. "Al" Thrasher AwardsUp to USD $550,000 for up to 3 years. This is for projects that are changing pediatric clinical care. Each award is a novel approach to problems plaguing pediatrics. The award is open to applications focusing on any disease or topic within the umbrella of pediatrics, both in and outside the United States. Ideal applications address significant health problems, offering the potential for practical solutions to these problems. Typically, the primary outcome is a health outcome in children. Solutions should be innovative and have the potential for broad applicability with low barriers to implementation. Projects with a shorter distance to clinical applicability are given priority.​ Hypothesis-driven research is critical, exploratory, or hypothesis-generating research will not be competitive. Spring 2025 cycle: Concept Submission (July 16, 2024); Full Proposal (October 22, 2024).
International Society for Emergency Medicine (SAEM) Foundation (SAEMF): Various Opportunities$6,000 over a one-yearSAEMF/Academy for Diversity and Inclusion in Emergency Medicine (ADIEM) Research Grant: This is to support research that evaluates the state of diversity and inclusion in the field of Emergency Medicine, evaluates interventions to improve diversity and inclusion in Emergency Medicine, or addresses disparities in healthcare outcomes in the practice of Emergency Medicine among underrepresented or marginalized groups.For all opportunities: August 1, 2024.
$20,000 for 1 yearMedical Toxicology Foundation (MTF) Toxicology Research Grant: This is to support research that advances the science of medical toxicology in emergency medicine. The goals are to foster collaboration between members of the American College of Medical Toxicology (ACMT) and SAEM and to advance the science of medical toxicology as it relates to all aspects of emergency medicine.
$20,000 for 1 yearEducation Project Grant: This is to support innovation in teaching, education, and educational research in emergency medicine for faculty-, fellow-, resident- and medical student-level learners. The mission of the grant is to provide support for a medical education research project.
$100,000 for 2 yearsEducation Research Training Grant: This is to support a fellow or junior faculty member in education research training, including pursuit and preferably completion of an advanced degree in education.
$100,000 for 1 year SAEMF Emerging Infectious Disease and Preparedness Grant: This is to support emergency care research related to emerging infectious disease, such as influenza, COVID-19, and other bacterial or viral infections. This award is not limited to specific conditions and may study an infectious disease at any point in its epidemiologic trajectory.
$150,000 for 2 yearsResearch Large Project Grant: This is to support an emergency medicine faculty member to conduct a large-scale research project to advance his/her career and subsequently obtain federal funding by developing pilot data.
Up to $300,000 per year for 2 years.Research Training Grant: This is to support the development of a researcher in emergency medicine.
International American Psychological Foundation (APF): Various OpportunitiesUSD $10,000. Scott and Paul Pearsall Grant: Supports graduate and early career work that seeks to increase the public’s understanding of the psychological pain and stigma experienced by adults living with visible physical disabilities, such as cerebral palsy. Applicants must be a full-time graduate student in good standing at an accredited university or an early career psychologist no more than 10 years post October 2, 2024.
USD $9,500. Dr. Diana Slaughter Kotzin and Mr. Joseph G. Kotzin Fund Grant: Supports research, practice, or education of an early career psychologist on the topic of child and youth suicide among African Americans. Early career psychologists no more than 10 years postdoctoral are eligible to apply. Value: USD $9,500.
InternationalU.S. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP) Pre-Announcement: FY24 Spinal Cord Injury Research Program (SCIRP)Single PI Option: Up to USD $3.0M for up to 4 years; Early-Career Partnering PI Option: Up to USD $3.1M for up to 4 years.Clinical Trial Award: Supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of spinal cord injury (SCI). Deadlines will be available when the announcements are released.
Single PI Option: Up to USD $1.25M for up to 3 years; Early-Career Partnering PI Option: Up to USD $1.35M for up to 3 years.Clinical Translation Research Award: Supports high-impact and/or new/emerging clinical research that may not be ready for a larger-scale clinical trial and for which feasibility/pilot/optimization studies are necessary.
Single PI Option: Up to USD $1.25M for up to 3 years; Early-Career Partnering PI Option: Up to USD $1.35M for up to 3 years.Translational Research Award: Funds studies that accelerate the movement of promising ideas in SCI research toward clinical application.
Single PI Option: Up to USD $500,000 for up to 3 years; Early-Career Partnering PI Option: Up to USD $600,000 for up to 3 years.Investigator-Initiated Research Award: Funds research that has the potential to make an important contribution to SCI research, patient care, and/or quality of life.
InternationalDoD Pre-announcement: Amyotrophic Lateral Sclerosis Research Program for FY24 (Multiple Opportunities)Up to $2,000,000 for up to 4 years.Pilot Clinical Trial Award: 1) Supports exploratory clinical trials of novel therapeutics or devices to demonstrate feasibility and inform the design of more advanced trials in ALS. 2) Supports clinical trials that may optimize aspects of multi-disciplinary ALS care or therapies for symptom management. 3) Must support a clinical trial and may not be used for preclinical research studies. Deadlines will be available when the announcements are released.
Up to $750,000 for up to 3 years.Clinical Outcomes and Biomarkers Award: 1) Supports development, improvement, and validation of clinical outcomes and/or biomarkers to enrich clinical trials in ALS. 2) Biomarker analysis can be relevant to a specific therapeutic or a specific ALS subtype and does not have to broadly apply to all patients. 3) A description of the biomarker category and intended context of is an important component.
Up to $1,500,000 for up to 3 years.Therapeutic Development Award: 1) Supports secondary preclinical validation and/or Investigational New Drug (IND)-enabling studies of therapeutics for ALS. 2) Preliminary data are required including therapeutic efficacy in at least one ALS model system. 3) Mechanism-specific predictive/cohort-selective, target engagement, and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component. If mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be described.
Up to $600,000 for up to 2 years.Therapeutic Idea Award: 1) Supports highly innovative, hypothesis-driven preclinical therapeutic development in ALS. 2) Projects focusing primarily on ALS pathophysiology, without consideration of therapeutic development, are outside the scope of this award mechanism.
InternationalDoD Pre-announcement: Peer Reviewed Alzheimer's Research Program for FY24 (Multiple Opportunities)Up to $1,400,000 for up to 4 yearsTransforming Care Award: Supports person-centered research that prioritizes the individual with AD/ADRD, their care partner/caregiver, and/or both and clearly demonstrates feasibility and identifies a realistic approach to scaling and implementation. “Care” does not refer to medical care (such as medical interventions administered by a physician). Deadlines will be available when the announcements are released.
Up to $2,000,000 for up to 4 years.Transforming Diagnosis Award: Supports research to reduce barriers and improve diagnosis and prognosis of dementia of AD/ADRD following military service and/or TBI.
Up to $1,000,000 for up to 3 years.Transforming Research Award: Supports high-impact research with high impact aimed to identify, validate, and/or mitigate risk factors which may contribute to dementia onset.
International U.S. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP) Pre-Announcement: FY24 Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP)

Applications submitted to the FY24 TBIPHRP must address one or more of the Focus Areas listed on the TBIPHRP website, not all ow which will be applicable to every opportunity.
Research Level 1: Up to USD $500,000 for up to 3 years; Research Level 2: Up to USD $2M for up to 4 years; Research Level 3: Up to USD $4M for up to 4 years. Please see the website for general descriptions of the scope of the research projects that would be appropriate to propose under each funding level.Clinical Trial Award: Supports the rapid implementation of clinical trials with the potential to have a significant impact on psychological health conditions and/or TBI through clinical applications, including healthcare products, technologies, and/or practice guidelines. Deadlines will be available when the announcements are released.
$5M for up to 4 years.Focused Program Award Award: Supports high-impact and/or new/emerging clinical research that may not be ready for a larger-scale clinical trial and for which feasibility/pilot/optimization studies are necessary Supports the development of a synergistic, multidisciplinary research program with the potential to have a significant impact on TBI and/or PH.
Up to USD $2.5M for up to 4 years.Health Services Research Award: Bridges the gap between research, practice, and policy by building a knowledge base on how interventions and clinical practices/guidelines and policies can be deployed to targeted populations at the appropriate time at the point of need.
Research Level 1: Up to USD $500,000 for up to 3 years; Research Level 2: Up to USD $1M for up to 4 years. Please see the website for general descriptions of the scope of the research projects that would be appropriate to propose under each funding level.Translational Research Award: Supports the conversion of research findings in psychological health and/or TBI into clinical applications, including health care products, technologies, and/or clinical practice guidelines.
Research Level 1: Up to USD $700,000 for up to 3 years; Research Level 2: Up to USD $1.5M for up to 4 years. Please see the website for general descriptions of the scope of the research projects that would be appropriate to propose under each funding level.Emerging Research Award: Advances research in emerging topics in in traumatic brain injury and/or psychological health, with a unique set of topic areas aligned with TBIPHRP goals (see website for details).
InternationalDoD Pre-announcement: The Lung Cancer Research Program (LCRP): Various Award Mechanisms

The FY24 Defense Appropriations Act provides funding for the LCRP to support innovative, high-impact lung cancer research
Up to $120,000 for 1 yearConcept Award: Supports highly innovative, non-incremental, high risk/potentially high-reward lung cancer research. Deadlines will be available when the announcements are released.
Up to $375,000 for up to 3 yearsCareer Development Award: Supports early-career, independent investigators to conduct research under mentorship of an experienced lung cancer researcher.
Up to $525,000 for up to 3 yearsIdea Development Award: Supports new ideas in the early stages of development representing innovative, high-risk/high-gain research.
Level 1: Up to $900,000 for up to 3 years;
Level 2 (clinical trial option): Up to $1.2M for up to 4 years
Patient-Centered Outcomes and Survivorship Award: Supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations.
Up to $650,000 for up to 3 yearsTranslational Research Award: Supports high-reward studies that span the spectrum of behavioral health science, survivorship, and health outcomes/comparative effectiveness research, including quality of life, symptom and side effect management, resilience, and co-morbid conditions and examining the physical, psychological, social and economic effects of lung cancer.
InternationalBiogen: Various Opportunities--Biogen considers requests in Biosimilars (Dermatology, Gastroenterology, Ophthalmology, Rheumatology), Multiple Sclerosis, and Spinal Muscular Atrophy in these areas:
Medical Education: Supports independent medical educational activities for HCPs and researchers. Medical education may be accredited or non-accredited.
Patient Education: Supports independent educational activities for patients or caregivers.
General Grant: Supports a project or program that does not fit any of the other defined grant categories.
April 15, August 15, November 1.
InternationalAmerican Psychoanalytic Association (APsaA) Fund for Psychoanalytic Research: Research GrantUSD $20,000 for 1 year.This is for a specific project building upon psychoanalytic principles or directly investigating the process and/or outcome of psychoanalytically informed treatments. The Fund conceives of psychoanalytic research along the broadest lines, including: scholarly and empirical investigative contributions that can advance knowledge of psychoanalytic theory, practice, and links between psychoanalysis and neighboring disciplines such as developmental psychology or neuroscience.May 1 and December 31 of each year.
InternationalAlloSource: Investigator Initiated Research (IIR) Grant ProgramGrant requests may include project funding and/or implantable tissue.AlloSource is working closely with physicians and scientists across multiple orthopedic therapies to continuously improve and bring new allografts to the market, while simultaneously maximizing the gift of donation.This program accepts grant proposals for Investigator Initiated clinical research studies of AlloSource tissue and/or post-market product lines. will collaborate with the Investigator to help implement the proposed research project.Rolling Deadline
InternationalSolving Kids' Cancer Therapeutic Development Initiative (TDI)$50,000 to $500,000 USD for up to 2 years.Solving Kids' Cancer is a nonprofit organization with a track-record of funding novel clinical research for children diagnosed with high-risk solid tumors specifically neuroblastoma, brain tumors and sarcomas. The TDI's goal is to support innovative early phase clinical studies that are high on the risk/reward spectrum. Priority is given to proposals that introduce novel therapeutic agents and modalities and have a strong potential to improve treatment outcomes.Preliminary Proposal Deadline: Rolling
InternationalÖssur Orthopaedic Research Grant Program--This provides funding for scientific inquiry in the areas of lower extremity biomechanics, dynamic/active rehabilitation, ortho biologics, functional bracing, clinical patient outcomes, and, related healthcare economics.Rolling Deadline
InternationalAesculap Implant Systems Investigator-Initiated Study Program (IIS)Dependent on the type of research and availability of support.This supports researchers interested in conducting studies of their own design, which promotes the advancement of medical and scientific knowledge related to Aesculap's products and therapeutic areas of focus: Neurosurgery; Surgical Technologies; Closure Technologies; Orthopaedics; Spine; Biologics.Continuous
InternationalBausch + Lomb Grants--• Educational Grants: These contribute to the improvement of patient care and advances in the use of healthcare products. Grand-rounds, lectures, symposiums and workshops are funded to educate medical students, university faculty, physicians, nurse practitioners, optometrists, ophthalmologists, allied health professionals, optical research scientists and associations of optometry and ophthalmology about improvements in ocular health.
• Independent Research Grant: These empower the global research community to develop new treatments and technological advancements in ocular health. Research Grants have been funded by to improve consumers’ standard of care, efficacy, patient satisfaction, safety and vision performance.
Rolling Deadlines. Allow 6-12 weeks for proposal review and decision.
InternationalHorizon Europe Pillar II: Global Challenges and European Industrial CompetitivenessWithin each cluster are a number of calls, which have unique criteria, budgets, and deadlines.Canadian researchers can now apply for and receive funding directly from this program. Pillar II funding is organised into 6 clusters (i.e., themes), including Cluster 1: Health. A consortium of at least three partners is needed to apply: at least one must be from an EU country and two must be from different EU or associated countries (e.g., Canada). Canadian applicants can be the lead or a partner on proposals. Eligible applicants include universities, research institutes, NGOs, SMEs, governmental organisations, among many others, depending on the call.Within each cluster are a number of calls, which have unique criteria, budgets, and deadlines.
NIHNIH Parent Announcements--This supports support research to: 1) understand the mechanisms and the pathogenesis of cardiometabolic health and cardiovascular disease (CVD) risk in vulnerable groups throughout transitionary phases, from pre-adolescence (6-10 years) through adolescence (11-18 years) to young adulthood (19-39 years), and 2) develop precision prevention interventions (at the individual and populations levels) to address cardiovascular and cardiometabolic risk across these transitionary phases.Standard dates apply unless otherwise stated.
NIHNIH: Psychedelics Treatment Research in Substance Use Disorder (UG3/UH3 Clinical Trials Optional)Up to USD $2M for up to 3 years.This opportunity aims to support the development of classic psychedelics (e.g., psilocybin, LSD), empathogens (e.g., MDMA), dissociatives (e.g., ketamine and related compounds), and other hallucinogens (e.g., ibogaine and its analogues) (henceforth “psychedelics”) as new treatment options for Substance Use Disorder (SUD). Applications may include the evaluation of an existing psychedelic, a new formulation, or a new psychedelic compound. The application can be at a preclinical and/or clinical phase of medication development.February 28, 2024.
NIHNIH Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)--This encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.March 7, 2024.
NIHNIH Notice of Special Interest (NOSI): Telehealth in Cancer Care--This supports investigator-initiated applications for conducting research on the use of telehealth in cancer-related care. Studies focused on populations that experience inequities in access to care and have worse cancer outcomes compared to the general population are strongly encouraged.This notice applies to subsequent receipt dates through March 8, 2024.
NIHNIH Notice of Special Interest (NOSI): Validation of Digital Health and Artificial Intelligence Tools for Improved Assessment in Epidemiological, Clinical, and Intervention Research--This is to encourage grant applications to support the evaluation of the utility and validity of digital health and artificial intelligence (AI) tools and technologies in epidemiological, clinical, and intervention research. The intent is to support the addition of new measurement modalities to evaluate existing and recently developed but not yet validated digital health and AI tools such as sensor technologies, smartphone applications, software as a medical device (SaMD), and AI algorithms.This Notice applies to due dates until March 9, 2024.
NIHNIH: Implementation Research on Noncommunicable Disease Risk Factors among Low- and Middle-Income Country and Tribal Populations Living in City Environments (R01 Clinical Trial Optional)--This is for implementation research focused on addressing risk factors for common noncommunicable diseases (NCDs) in World Bank-defined low- and middle-income countries (LMICs) and American Indian/Alaska Native (AI/AN) populations in the United States (US). Air, water, and soil pollution; lack of greenspace; urban heat islands; lack of safe infrastructure for walking, cycling, and active living; lack of access to healthcare facilities, lack of health insurance, and cost of medications; housing condition; and wide availability of tobacco, alcohol, and unhealthy foods and beverages contribute to the NCD epidemic in city environments. This NOFO supports applications that propose implementation research to reduce the risks of NCDs in the context of cities in LMICs and/or among AI/AN populations in US cities, with the potential to equip policymakers and practitioners with evidence-based strategies for prevention and/or management of NCDs among disadvantaged populations globally. March 11, 2024.
NIHNIH NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)--The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). February 9, 2024; May 7, 2024.
NIHNIH Notice of Special Interest (NOSI): Harnessing Big Data to Halt HIV-- This is to promote and support innovative methods in Big Data Science (BDS) to identify unappreciated biomedical, behavioral, social patterns and other social determinants that shed light on HIV acquisition, transmission, the development of comorbidities, and long-term viral control as in the HIV treatment continuum. BDS approaches can bring together data to evaluate the complex interplay between individual, contextual, and structural factors influencing the epidemiology of risk and care. This NOSI will support the establishment of BDS standards, bioinformatics data tools, machine-learning algorithms, mathematical modeling, advanced epidemiology and statistical analytic methods, and consideration and application of privacy and ethical issues in the use of public and personal data in the context of HIV research.This notice applies to subsequent receipt dates through May 7, 2024.
NIHNIH Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)-- This Grant program supports exploratory and innovative research projects, which fall within the missions of the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute of Mental Health (NIMH). Only applications that:
- fall within the scientific mission of the NINDS (seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease for all people)
- or align with Goal 1 (Define the Brain Mechanisms Underlying Complex Behaviors) of the NIMH 2020 Strategic Plan will be accepted and considered for funding.
- The NIMH Division of AIDS Research also invites applications in the program areas outlined on the HIV Neuropathogenesis, Genetics, and Therapeutics Branch webpage that are aligned with the NIH Strategic Plan for HIV and HIV-related Research.
Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community.
This notice applies to subsequent receipt dates through May 7, 2024.
NIHNIH Notice of Special Interest (NOSI): Maximizing the Scientific Value of Secondary Analyses of Existing Cohorts and Datasets in Order to Address Research Gaps and Foster Additional Opportunities in Aging Research--This is to encourage the use of existing cohorts and datasets for well-focused secondary analyses to investigate novel scientific ideas and/or address clinically related issues on: (1) aging changes influencing health across the lifespan (e.g., Alzheimer’s disease and Alzheimer's disease-related dementias (AD/ADRD)), (2) diseases and disabilities in older persons, and/or (3) the changes in basic biology of aging that underlie these impacts on health (the hallmarks of aging).This Notice applies to due dates on or after June 5, 2023 and subsequent receipt dates through May 8, 2024.
NIHNIH NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)--This supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data. This notice applies to subsequent receipt dates through May 7, 2024.
NIHNIH Notice of Special Interest (NOSI) regarding the Use of Human Connectome Data for Secondary Analysis--This encourages secondary analyses of data from the Human Connectome Project (HCP), including the multiple datasets in the Lifespan Human Connectome projects and the Human Connectomes Related to Human Disease. Applicants beyond the groups that originally collected the data are encouraged to apply. The analyses will serve to generate and evaluate hypotheses about the complex interrelationships among: brain structure, function and connectivity; cognitive, affective, sensory and motor processes; environmental factors; life event, social and psychosocial factors; genomic data, and clinical symptoms during development, aging, or disease.This notice applies to receipt dates through May 8, 2024.
NIHNIH Notice of Special Interest (NOSI) HIV/AIDS in the Era of COVID-19: When Pandemics Collide--This is to communicate special interest in epidemiology investigations to quantify the impact of the COVID-19 pandemic on HIV prevention, incidence, transmission, and outcomes. This NOSI encourages research on the impact and strategies needed to adapt the HIV/AIDS response through agile and innovative support of prevention and care and the maintenance of sustained HIV viral suppression during the COVID-19 pandemic.This notice applies to due dates on or after September 7, 2021 and subsequent receipt dates through May 8, 2024.
NIHNIH Notice of Special Interest (NOSI): Promoting Vaccine Access, Acceptance and Uptake among Children, Adolescents, Pregnant and Lactating Women, and Persons with Disabilities--This NOSI encourages applications that address dimensions of access, acceptance and uptake of CDC-recommended vaccines among infants, children, adolescents, pregnant and lactating women, and persons with disabilities, especially among populations who are underserved or experience health disparities.This notice applies to due dates on or after September 8, 2021 and subsequent receipt dates through May 8, 2024.
NIHNIH Notice of Special Interest: Advancing Health Communication Research on HIV Prevention, Treatment and Cure--To address knowledge gaps that will improve HIV outcomes, this calls for research that will improve scientific understanding of health communication as it relates to ongoing HIV prevention, diagnosis, treatment and cure efforts, as well as research on communication, dissemination and implementation factors that are required for successful public understanding, acceptance and uptake of HIV-related interventions.This notice applies to due dates on or after April 8, 2021 and subsequent receipt dates through May 8, 2024.
NIHNIH Notice of Special Interest (NOSI): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments--The National Cancer Institute (NCI) in supporting implementation research related to cancer prevention and control in low- and middle-income countries. NCI encourages applications that pursue innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines in low-resource settings.This notice applies to subsequent receipt dates through May 8, 2024.
NIHNIH Notice of Special Interest (NOSI): Small Research Grants for Innovations in Healthy Longevity Research--This invites applications for small research grants that align with the goals of the National Academy of Medicine's Healthy Longevity Grand Challenge, as well as the National Institute on Aging's (NIA) interests in supporting research to promote a long healthspan and functional independence in both aging and Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD).This Notice applies to due dates on or after July 16, 2023 and subsequent receipt dates through May 8, 2024.
NIHNIH Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed)--The purpose of this Funding Opportunity Announcement (FOA) is to encourage innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. February 5, 2024; June 5, 2024.
NIHNIH Notice of Special Interest (NOSI): Dissemination and Implementation Research to Advance Mental, Emotional, and Behavioral Health Preventive Interventions in School Settings--The purpose is to stimulate dissemination and implementation research to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based preventive interventions to support children's mental, emotional, and behavioral (MEB) health in school settings. This Notice applies to due dates until June 5, 2024.
NIHNIH Notice of Special Interest (NOSI) - Emerging and Existing Issues of Coronavirus Disease 2019 (COVID-19) Research Related to the Health and Well-Being of Women, Children and Individuals with Physical and/or Intellectual Disabilities--The purpose is to provide an avenue for researchers to pursue funding to conduct research addressing emerging and existing COVID-related issues among pregnant and lactating people, infants, children and adolescents, and individuals with physical and/or intellectual disabilities. Please see the NOSI for the areas of interest in these populations.This notice applies to due dates on or after June 5, 2022 and subsequent receipt dates through June 6, 2024.
NIHNIH Notice of Funding Opportunity (NOFO): BRAIN Initiative- Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)--This NOFO solicits applications to develop informatics tools for analyzing, visualizing, and integrating data related to the BRAIN Initiative (The Brain Research through Advancing Innovative Neurotechnologies) or to enhance our understanding of the brain. It is expected that the application of these new tools and technologies will ultimately lead to new ways to treat and prevent brain disorders.June 7, 2024.
NIHNIH Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health--This calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider, healthcare system, and community levels.This notice applies to subsequent receipt dates through June 8, 2024.
NIHNIH: Multi-Scale Models Bridging Levels of Analysis in Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R01 Clinical Trial Not Allowed)--This notice of funding opportunity (NOFO) invites applications proposing to establish multi-scale computational models recapitulating dynamic changes associated with aging and Alzheimer’s disease (AD) and AD-related dementias (ADRD). This broad scope encompasses a variety of computational approaches—such as mathematical and computational modeling, image analysis, artificial intelligence, and machine learning—to better understand aging processes and AD/ADRD across molecules, cells and networks, and cognition and behavior.June 13, 2024.
NIHNIH BRAIN Initiative: Standards to Define Experiments Related to the BRAIN Initiative (R01 Clinical Trial Not Allowed)--This aims to develop standards that describe experimental protocols conducted as part of the BRAIN Initiative. It is expected that applications will solicit community input at all stages of the process. It is recommended that the first step of standard development will involve sharing data between different key groups in the experimental community in order to ensure that the developing standard will encompass the data collection efforts of those groups. The developed standard is expected to be broadly disseminated for use and widely available.June 14, 2024.
NIHNIH Notice of Special Interest (NOSI): Advancing Research for Amyotrophic Lateral Sclerosis (ALS)--The National Institute of Neurological Disorders and Stroke (NINDS) encourages applications to advance research activities relevant to strategic priorities for the ALS research community identified in a recent planning effort of NINDS, including Data Harmonization, Curation, and Analysis; Development of Biomarkers and Biomarker Signatures to Optimize Clinical Trials and Clinical Care Decisions; and Therapy Development for ALS.This notice applies to due dates on or after March 14, 2023, and subsequent receipt dates through June 24, 2024.
NIHNIH Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)--This NOSI seeks to support investigation into the factors and molecular mechanisms that address the heterogeneity dictated by the host resilience. Research on general host responses to injurious challenges and their effects on lung function as well as mechanisms that impact susceptibility to ARDS is not considered to be responsive to this announcement.This notice applies to receipt dates through July 5, 2024.
NIHNIH Notice of Funding Opportunity (NOFO): Devide Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)--This seeks to support research into neuromodulatory technologies to treat SUDs. These technologies include, but are not limited to, transcranial magnetic stimulation, transcranial direct current stimulation, vagal stimulation, deep-brain stimulation, focused ultrasound, and others. Also of interest are technologies that may not directly modify neuronal function but report on or alter neurophysiology that affect outcomes. Activities supported under this NOFO can be found here. August 13, 2024.
NIHNIH: Mechanistic Studies on Social Behavior in Substance Use Disorder (SUD): Various Opportunities


The purpose of this notice of funding opportunity (NOFO) is to solicit applications proposing mechanistic transdisciplinary research on Substance Use Disorders (SUDs).
Up to $425,000 for up to 5 yearsR01 Clinical Trials Not Allowed: This is intended to support basic or translational research in non-human animal models, including secondary analysis of data from research in animal models. that provides mechanistic insights into social behavior and its relationships with the onset, trajectory and impact of SUDs and comorbidities. This is intended to support basic or translational research in non-human animal models, including secondary analysis of data from research in animal models.Letter of Intent: July 14, 2024;
Full Application: August 14, 2024.
--R01 Clinical Trials Optional: This will support projects that investigate social behavior and its relationships with the onset, trajectory, and impact of SUDs and comorbidities. It is intended to support basic or early translational studies that may, but need not, be considered NIH clinical trials; this may include mechanistic clinical trials, observational studies, or secondary analysis of human data.
--R01 Basic Experimental Studies with Humans (BESH) Required: This is to solicit applications proposing studies that meet the NIH definition of Basic Experimental Studies involving Humans (BESH) and consist of mechanistic, transdisciplinary research on social behavior and its relationships with the onset, trajectory, and impact of SUDs and comorbidities.
NIHNIH Notice of Special Interest (NOSI): Using Data to Advance HIV Epidemic Knowledge and Program Planning--This encourages grant applications proposing research that makes use of available, large data sets with the objective of improving HIV epidemic modeling and service planning, with greater attention to the role of substance use. National Institute on Drug Abuse (NIDA) is interested in applications that make use of existing data, such as epidemiologic cohorts, clinic cohorts and longitudinal follow-up studies of interventions, as well as other publicly available sources of data including data warehouses and commercial data sources. Substance use should be a key component of any research supported by this NOSI.This notice applies to subsequent receipt dates through September 7, 2024.
NIHNIH Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19--National Institute on Drug Abuse (NIDA) is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19. This notice applies to due dates through September 7, 2024.
NIHNIH Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection--This NOSI encourages research to understand:
• The risks that smoking or vaping tobacco or marijuana may have on acquiring the COVID-19 infection.
• The medical consequences, co-morbidity, and complications of COVID-19 infection in individuals who smoke or vape tobacco or marijuana.
• The medical consequences of COVID-19 in individuals who smoke and vape with comorbid conditions such as: SUD, HIV and other immunosuppressive diseases, mental health disorders, diabetes mellitus, obesity, cardiovascular, pulmonary, renal, and hepatic pathologies, as well as cancer.
This notice applies to due dates through September 8, 2024.
NIHNIH Basic Research in Cancer Health Disparities--This encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities.
- R01 Clinical Trial Not Allowed: These research project grants will support innovative studies designed to investigate biological/genetic bases of cancer health disparities.
- R21 Clinical Trial Not Allowed: This provides support for early-stage exploratory projects that lead to future in-depth mechanistic studies (such as R01 projects) of the biology of cancer health disparities.
- R03 Clinical Trial Not Allowed These small research grants will support projects on cancer health disparities that can be carried out in a short period of time with limited resources.
Standard dates apply until September 8, 2024.
NIHNIH Notice of Special Interest (NOSI): Behavioral Economics for Implementation Research (BEIR) to improve use of Evidence-Based Practices for heart, lung, blood, and sleep (HLBS) conditions--National Heart, Lung, and Blood Institute (NHLBI) encourages applications that recognize the importance of cultural context, patterns of behavior change, and motivators for change across decision-making levels, including individuals (e.g., patients, parents, clinicians, others), groups, healthcare systems and/or communities.This notice applies to subsequent receipt dates through September 8, 2024.
NIHNIH Notice of Special Interest (NOSI): International Research Collaboration on Drug Abuse and Addiction Research--The purpose of this notice is to encourage collaborative research applications that take advantage of opportunities outside of the US. Applications examining all areas of National Institute on Drug Abuse (NIDA)-supported research addressing the causes, consequences, treatment, and prevention of drug use, misuse, and addiction are encouraged. Projects should be conducted through newly formed or well-established partnerships between an investigator in a US-based institution and a scientist working in another country.This notice applies to subsequent receipt dates through September 8, 2024.
NIHNIH BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed)--This seeks the development of theories, computational models, and analytical tools to derive understanding of brain function from complex neuroscience data. Proposed projects could develop tools to integrate existing theories or formulate new theories; conceptual frameworks to organize or fuse data to infer general principles of brain function; multiscale/multiphysics models to generate new testable hypotheses to design/drive future experiments; new analytical methods to substantiate falsifiable hypotheses about brain function.September 12, 2024.
NIHNIH Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)--This solicits applications from research partnerships formed by academic and industrial investigators to accelerate the development and adoption of promising bioengineering tools and technologies that can address important biomedical problems. The goal of the program is to support technological innovations that deliver new capabilities, which can realize meaningful solutions within 5-10 years. Projects may span the development in the research settings, validation, translation into clinical settings as needed, and incorporation of these solutions as endpoints into research protocols to enhance our understanding of life science processes or the practice of medicine to benefit patients.May 24, 2024; September 26, 2024.
NIHNIH: Notice of Special Interest: Health Influences of Gender as a Social and Structural Variable--Applications should have a clear and central focus on social and/or structural domains of gender as demonstrated through a primary aim of EITHER (1) elucidating modifiable factors in gender-related health disparities OR (2) developing, testing, or implementing social or structural interventions to mitigate gender-related health disparities OR (3) investigating the interactions between multiple social and structural domains of gender (e.g., gender roles and gender inequity; power and gender relations). In each of these potential areas of focus, intersectional approaches to gender-related social and structural variables are strongly encouraged.
Topics of particular interest are:
• Community-led interventions to address gender-related health disparities
• Development or testing innovative, intersectional approaches to addressing gender-related health disparities
• Projects to enhance understanding of health disparities based in structural sexism, gender norms, relational power dynamics, and/or gender inequities
• Projects to develop, test, implement and/or evaluate interventions aimed at mitigating health disparities based in structural sexism, gender norms, relational power dynamics, and gender inequities. Interventions can target one or multiple levels of gender-related variables
• Gendered influences on prevention, treatment, and outcomes of female-specific conditions and diseases more common in women (e.g., fibroids, autoimmune diseases)
• Research that evaluates one or more health prevention and treatment outcomes in light of legal and policy issues at the intersections of public health surveillance, care delivery, and social and structural domains of gender
September 30, 2024.
NIHNIH: Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)--This opportunity is for applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic, clinical, or epidemiological cancer research. The emphasis of this NOFO is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. April 1, 2024; October 1, 2024.
NIHNIH: Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)--This opportunity invites grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic, clinical, or epidemiological cancer research. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. April 1, 2024; October 1, 2024.
NIHNIH: Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)--This opportunity solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. April 1, 2024; October 1, 2024.
NIHNIH: Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)--This opportunity solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses.April 1, 2024; October 1, 2024.
NIHNIH HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)_The focus is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target.February 2, 2024; June 4, 2024; October 2, 2024.
NIHNIH BRAIN Initiative: Targeted BRAIN Circuits Projects--R34 Clinical Trials Not Allowed: For applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying hat, if successful, would support, enable, and/or lay the groundwork for a potential, subsequent Targeted BRAIN Circuits Projects - TargetedBCP R01
R01 Clinical Trial Not Allowed: For research projects that seek to understand how circuit activity gives rise to mental experience and behavior using innovative, methodologically-integrated approaches. The goal is to support adventurous projects that can realize a potentially transformative outcome within 5 years.
June 28, 2024; October 2, 2024.
NIHNIH: Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)--This encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, digital health and data science, and implementation science.June 5, 2024; October 5, 2024.
NIHNIH Exploratory Grants in Cancer Epidemiology (R21 Clinical Trial Optional)--Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) encourages the submission of exploratory/developmental research grant (R21) applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, interventions, methodologies, models, or applications that could have a major impact on a field of cancer research (e.g. epidemiologic, biomedical, behavioral, health care delivery or clinical).June 7, 2024; October 8, 2024.
NIHNIH Notice of Special Interest (NOSI): Research on Interprofessional Teamwork and Coordination During Cancer Diagnosis and Treatment--The purpose is to stimulate research that identifies effective strategies for improving interprofessional teamwork and addresses care coordination challenges within care settings and between care settings (e.g., between tertiary care and community settings) or during care transitions (e.g., from inpatient to outpatient care). Research in this area should advance actionable knowledge about how to design and carry out effective, efficient interprofessional team-based cancer care that improves quality and patient outcomes. Research that is focused on the needs of racial/ethnic minority, medically underserved, or low-income populations and/or those receiving care in community settings (including, but not limited to, community-based cancer centers or clinics) is not required, but strongly encouraged.This notice applies to subsequent receipt dates through October 9, 2024.
NIHNIH Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)--The National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. Research on non-cancer outcomes, especially those related to aging (e.g., Alzheimer's, depression, hip fracture, osteoporosis and rheumatoid arthritis) may also be supported.February 13, 2024; June 11, 2024; October 11, 2024.
NIHNIH Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional)--This is to create a pipeline to accelerate the development and early validation of predictive tools and/or biomarkers to inform individual-level treatment selection among two or more existing therapeutics for depression. his phased inter-agency program will be milestone-based and provide support from multi-disciplinary teams to address scientific, technical, clinical, regulatory, and commercialization requirements.October 18, 2024.
NIHNIH Clinical Trial Readiness for Functional Neurological Disorders (FNDs) (U01 Clinical Trial Optional)--This invites researchers to submit prospective clinical projects that address critical needs for clinical trial readiness in FNDs. Projects appropriate for this funding opportunity announcement include the validation of biomarkers, endpoints and clinical outcome assessments that are fit-for-purpose and have a defined context of use for clinical trialsStandard dates apply until November 6, 2024.
NIHNIH Research on Current Topics in Alzheimer's Disease and Its Related DementiasThis invites applications proposing research on current topics in Alzheimer's disease (AD) and its related dementias (ADRD). Further information on the high-priority topics of interest will be announced through a series of Notices published subsequent to this announcement. Applications proposing research on topics beyond those specified in the notices will not be prioritized for funding.
R21 Clinical Trial Optional: For applications that need additional preliminary data with broader dissemination to establish them for more general use in this research field.
R01 Clinical Trial Optional
March 11, 2024; July 9, 2024; November 12, 2024.
NIHNIH: Effect of HIV and Substance Use Comorbidity on the Placenta and Maternal Outcomes (R01 Clinical Trial Optional)--This opportunity is for research targeted at elucidating the effect of HIV and/or anti-retroviral therapy (ART)on the growth, development and functioning of the placenta in pregnant individuals with substance use/misuse, the impact of placental abnormalities on maternal outcomes, and the underlying mechanisms. Priority will be given to applications that propose research with the following features:
• Transdisciplinary research teams to foster the sharing of conceptual and/or technical expertise.
• The proposed research includes methods that examine causality across the variables of interest.
November 15, 2024.
NIHNIH Accelerating the Pace of Drug Abuse Research Using Existing Data--This invites applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. Primary data collection is not allowed for applications.
R21 Clinical Trial Optional
R01 Clinical Trial Optional
March 4, 2024; August 5, 2024; November 15, 2024.
NIHNIH: Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)--The opportunity invites Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this opportunity focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. June 11, 2024; November 15, 2024.
NIHNIH: Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)--This invites Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this NOFO focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this NOFO as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. June 11, 2024; November 15, 2024.
NIHNIH: Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)--This invites Cooperative Agreement (U24) applications for the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this NOFO focuses on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources. This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR NOFOs. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. June 11, 2024; November 15, 2024.
NIHNIH: Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)--This invites exploratory/developmental research grant applications (R21) for innovative informatics methods and algorithms to improve the acquisition, analysis, visualization, or interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, the emphasis of this NOFO is on supporting the development of novel informatics capabilities that involve a high degree of innovation that have the potential to accelerate or enhance research. June 11, 2024; November 15, 2024.
NIHNIH Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed)--This supports hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI).December 7, 2024.
NIHNIH Notice of Special Interest (NOSI): Technology Development for Cancer Control and Population Science Research--This is to encourage grant applications for the development of novel technologies to support the needs of cancer control and population sciences research including healthcare delivery research, surveillance research, behavioral research, cancer epidemiology, and population scale -omics research with the goal of driving innovation in this field.This notice applies to due dates on or after March 1, 2023 and subsequent receipt dates through December 31, 2024.
NIHNIH R21: Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)--The purpose of this is to promote development of innovative, enabling tools and technologies in the areas of kidney, urologic, and hematologic diseases. This notice applies to due dates on or after January 7, 2024 and subsequent receipt dates through January 07, 2025.
NIHNIH Neuromodulation/Neurostimulation Device Development for Mental Health Applications--This encourages applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently FDA-approved or cleared.
R01 Clinical Trial Not Allowed: For applicants who seek to propose a larger project. Applicants who seek to establish proof-of-concept should respond to the companion R21.
R21 Clinical Trial Not Allowed: This uses the R21 grant mechanism, encouraging shorter, higher-risk applications. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope.
Standard dates apply until January 8, 2025.
NIHNIH - Notice of Special Interest (NOSI): Research on the Impact of Policy Changes and Emerging and Evolving Public Health Crises on NICHD Populations of Interest--This aims to study the effect of emerging and evolving public health crises and/or policy changes on the health, development, and well-being of populations of interest to the NICHD: neonates, infants, children, adolescents, and young adults, pregnant and post-partum and nursing people, individuals of reproductive age, and individuals with intellectual, developmental, or physical disabilities, as well as the families of these individuals.This notice applies to subsequent receipt dates through January 8, 2025.
NIHNIH Drug Discovery for Nervous System Disorders--NIMH, NIAAA, NIDA and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics ; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.
R01 Clinical Trials Not Allowed: Applicants with preliminary data may wish to apply using the R01 mechanism. High risk/high payoff projects that lack preliminary data may be most appropriate for the R21 mechanism.
R21 Clinical Trials Not Allowed: This will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies).
Standard dates apply until January 8, 2025.
NIHNIH Notice of Special Interest (NOSI): COVID-19 Pandemic Mental Health Research--National Institute of Mental Health (NIMH) is issuing this NOSI to highlight interest in basic, translational, intervention and services research relevant to the COVID-19 pandemic. NIMH is especially interested in research to provide an evidence base to understand how mental illness contributes to COVID-19 risk and mortality, how incident mental illness develops with COVID-19, and the development of scalable interventions to meet the public mental health needs during and resulting from the pandemic both specifically related to the virus but also at a broader population level that is impacted by stress, disruptions, and loss of lives in the pandemic. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH. Research is anticipated to focus on particularly vulnerable populations based on existing evidence of increased mental health symptoms and illness and preexisting and worsening health disparities.This Notice applies to subsequent receipt dates through January 8, 2025.
NIHNIH NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)--This is for investigator-initiated exploratory Phase 1 and Phase 2 clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). These trials must address questions within the mission and research interests of the NINDS. They may include studies of drugs and biologics, feasibility or preliminary efficacy studies of devices, and early studies of surgical, behavioral or rehabilitation therapies.This notice applies to due dates on or after February 8, 2024 and subsequent receipt dates through February 10, 2025.
NIHNIH Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed)--This encourages innovative pilot research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial pilot projects that address National Institute of Mental Health (NIMH) strategic priorities to strengthen the public health impact of NIMH-supported research as described in Goal 4 of the NIMH Strategic Plan.This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through February 16, 2025.
NIHNIH Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)--The study must address questions within the mission and research interests of the National Institute of Neurological Disorders and Stroke (NINDS) and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. NINDS is particularly interested in pragmatic study designs that utilize a cost-effective means of prospectively collecting observational data important to current clinical practice.This notice applies to due dates on or after February 20, 2024 and subsequent receipt dates through February 19, 2025.
NIHNIH Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01 Clinical Trial Not Allowed)--This invites researchers to submit applications for support of clinical studies that address critical needs for clinical trial readiness in rare neurological and neuromuscular diseases. These studies should result in clinically validated biomarkers and clinical outcome assessment measures appropriate for use in upcoming clinical trials.February 20, 2024; August 19, 2024; February 19, 2025.
NIHNIH Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed)--This will support technology transfer, preclinical immunogenicity and optimization studies, process development, analytical assay development, qualification, validation, testing, small scale pilot or engineering runs, CGMP manufacture in partnership with Pharma/ Biotech/Contract Manufacturing Organizations (CMO), quality assurance/quality control oversight, fill-finish activities, product release and storage, generation of reference standard, drug substance and drug product stability testing programs, Investigational New Drug (IND)-enabling studies, and regulatory submission preparation.March 15, 2024; March 14, 2025.
NIHNIH Tobacco Regulatory Science (R01 Clinical Trial Optional)--This is to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP).This notice applies to due dates on or after May 6, 2024 and subsequent receipt dates through May 2, 2025.
NIHNIH Notice of Special Interest (NOSI): Public Health Research on Cannabis--The National Institute on Drug Abuse (NIDA) is issuing this notice to encourage grant applications on the effects of changing cannabis laws and policies in the US and globally on public health.This notice applies to subsequent receipt dates through May 5, 2025.
NIHNIH Laboratories to Optimize Digital Health (R01 Clinical Trial Required)--This is intended to support the development of digital health test beds that leverage well-established digital mental health platforms and infrastructure to rapidly refine and optimize existing evidence-based digital health interventions and to conduct clinical research testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness particularly in populations who experience health disparities and vulnerable populations.Standard dates apply until May 8, 2025.
NIHNIH Notice of Special Interest (NOSI): Research to Prevent Drug Use, Misuse and Addiction--The National Institute on Drug Abuse (NIDA) is issuing this Notice to encourage grant applications in research on the prevention of risky drug use behaviors and addiction. The research may include studies to: 1) develop and test strategies to prevent the initiation of substance use, progression to substance use disorders, or to prevent substance use-related conditions such as HIV; 2) develop and test processes or strategies to implement, scale, and sustain evidence-based prevention in community, practice, and service systems;and,3) develop methods to conduct prevention science. Primary outcomes of interest for submitted applications include preventing initiation of substance use, misuse, and progression to disorder, as well as prevention of HIV infection.This notice applies to subsequent receipt dates through May 8, 2025.
NIHNIH Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening--This is to solicit applications proposing to strengthen the evidence base for preventive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and harms cannot be determined. It encourages the development and use of innovative and rigorous methods and approaches to close high priority evidence gaps to elevate screening services to a level suitable for a definitive grade or recommendation.This NOSI applies to subsequent receipt dates through May 8, 2025.
NIHNIH Notice of Special Interest (NOSI): Increasing Uptake of Evidence-Based Screening in Diverse Populations Across the Lifespan--This encourages highly innovative translational research focused on the delivery of multilevel interventions to improve uptake of evidence-based screening services that promote health equity and that are recommended by expert committees. At minimum, the proposed studies must: Include screening as a primary outcome; Inform the development of OR test an intervention or strategy that acts on at least two socioecological levels; and, Include OR test an intervention or strategy that demonstrates high potential for scalability and sustainability.This notice applies to subsequent receipt dates through May 8, 2025.
NIHNIH NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)--The purpose is for secondary data analysis using existing data sets from vision-related clinical trials, epidemiologic, and other clinical research studies. This may be used to develop new statistical methodologies or test hypotheses using existing data, but must not be used to support the collection of new data.Standard dates apply until May 8, 2025.
NIHNIH NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)--This supports applicants in their planning efforts to conduct collaborative large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies on eye/vision conditions. The grant may be used to support the development of a Manual of Procedures (MOP), as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention.Standard dates apply until May 8, 2025.
NIHNIH Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed)--This encourages innovative pilot research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial pilot projects that address National Institute of Mental Health (NIMH) strategic priorities to strengthen the public health impact of NIMH-supported research as described in Goal 4 of the NIMH Strategic Plan.Standard due dates apply until May 8, 2025.
NIHNIH Multi-Site Investigator-Initiated Clinical Trials: Various Opportunities--These support investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which must be relevant to the research mission of the National Heart, Lung, and Blood Institute (NHLBI).
Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)
Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI.
This notice applies to due dates on or after February 13, 2024 and subsequent receipt dates through June 11, 2025.
NIHNIH Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)--This supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials must be relevant to the research mission of the National Heart, Lung, and Blood Institute (NHLBI). This notice applies to due dates on or after February 13, 2024 and subsequent receipt dates through June 11, 2025.
NIHNIH NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)--This supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, comparative oncology, symptom management, or reduction of cancer disparities. It does not support research that focuses on basic cancer biology (such as studies of cancer-related pathways, molecular mechanisms, or mechanisms of metastasis), late-stage clinical trials, risk assessment studies, epidemiological studies, or studies of behavioral interventions.This notice applies to due dates on or after February 13, 2024 and subsequent receipt dates through June 12, 2025.
NIHNIH Dissemination and Implementation Research in Health--Supports studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through June 16, 2025.
NIHNIH Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)--This supports the phased development of in vivo assays to address translational gaps in treatment development for mental disorders. Support will be provided for assay development efforts that propose quantitative measures to assess alterations in neurophysiology/circuit activity that contribute to or reflect clinically relevant domains of function (e.g., cognitive function, impulsivity, motivation, etc.). It supports assays that measure brain functions that are evolutionarily conserved between a selected animal species and humans.This notice applies to due dates on or after February 21, 2024 and subsequent receipt dates through June 20, 2025.
NIHNIH HEAL Initiative Notice of Special Interest (NOSI): Development and Validation of Pain-Related Models and Endpoints to Facilitate Non-Addictive Analgesic Discovery--This is to encourage the development, validation, and replication of animal models that recapitulate the phenotypic and physiologic characteristics of a defined pain type/indication and/or disease-associated pain condition and endpoints or outcome measures that can be used there in.This notice applies to due dates on or after October 18, 2022 and subsequent receipt dates through June 25, 2025.
NIHNIH: Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional) --This initiative intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. This notice applies to due dates on or after February 27, 2024 and subsequent receipt dates through June 25, 2025.
NIHNIH Notice of Special Interest (NOSI): Enhancing Research on Deciphering Mechanisms of COVID-19-Associated Coagulopathy--This NOSI will support research that focuses on the basic mechanisms of COVID-19 associated thrombosis ranging from vascular endothelial cell injury, the host immune responses, to the coagulation and fibrinolysis systems. Identifying risk factors, or co-morbidities that predispose patients to COVID-19-Associated Coagulopathy (CAC) are also of interest.This notice applies to due dates on or after June 5, 2023 and subsequent receipt dates through July 5, 2025.
NIHNIH Notice of Special Interest (NOSI): Diagnostics and Disease Management Tools for Use in Underserved Populations--This seeks applications for diagnostics and disease management tools that have the power to deliver breakthroughs to enable prevention and treatment of heart, lung, blood and sleep diseases in underserved communities. Investigators will be required to engage community partners at the onset and throughout their research project.This notice applies to due dates on or after February 5, 2022 and subsequent receipt dates through July 6, 2025.
NIHNIH Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed)--This is to support high-risk, high-impact, early discovery research on vaccine approaches to prevent acquisition of or ongoing infection by HIV. In keeping with the high impact, high risk nature of the research, preliminary data are not required.August 2, 2024; August 1, 2025.
NIHNIH Notice of Special Interest (NOSI): Research on the Health of Sexual and Gender Minority (SGM) Populations--This encourages research that describes the biological, clinical, behavioral, and social processes that affect the health and development of SGM populations and individuals and their families, and that leads to the development of acceptable and appropriate health interventions and health service delivery methods that will enhance health and development of these populations.This notice applies to subsequent receipt dates through August 1, 2025.
NIHNIH Notice of Special Interest (NOSI): NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional)This NOSI supports innovative basic, clinical and translational research that may lead to improved therapies or preventive interventions for HIV in people with Substance Use Disorders. Applications responding to this must propose pioneering research that aligns with the NIH HIV/AIDS Research Priorities.This notice applies to due dates on or after July 15, 2023 and subsequent receipt dates through August 15, 2025.
NIHNIH Notice of Special Interest (NOSI): Studies of Cellular/Molecular Pathobiological Mechanisms of Lung Diseases Using Human 3-Dimensional Cellular Systems (R01)--This promotes research characterizing the pathobiological processes and mechanisms that drive the onset and progression of lung diseases at a molecular/cellular level, providing a systems-level understanding by studying experimental systems with cellular heterogeneity and 3-D architecture. Projects will utilize ex vivo preparations (e.g., thin human lung slices) or 3-D multi-cellular in vitro systems (e.g., organoids) of human lung cells and will employ state-of-art multi-omics measures (e.g., spatial or single cell/nucleus omics). This notice applies to due dates on or after September 25, 2022 and subsequent receipt dates through September 7, 2025.
NIHNIH: Notice of Special Interest (NOSI): Preventive Interventions to Address Cardiometabolic Risk Factors in Populations that Experience Health Disparities--The purpose of this NOSI is to solicit projects on preventive interventions that address cardiometabolic risk factors in populations that experience health disparities.This notice applies to due dates on or after October 5, 2022 and subsequent receipt dates through September 8, 2025.
NIHNIH Notice of Special Interest (NOSI): Epidemiology of Drug Abuse--This encourages the submission of research project applications that enhance our understanding of the nature, extent, distribution, etiology, comorbidities, and consequences of drug use, misuse, and addiction across individuals, families, communities, and diverse population groups. Of interest are applications that address multiple levels of risk, resilience, and causation across scientific disciplines, and that apply novel methods to advance knowledge of the interplay among genetic, environmental, neurobiological, and developmental factors and associated health and disease outcomes.This Notice applies to applies to due dates on or after June 5, 2022 and subsequent receipt dates through September 8, 2025.
NIHNIH Notice of Special Interest (NOSI): Leveraging Data Science to Bring Actionable Insights for Substance Use Prevention and Treatment--This supports research projects that 1) leverage data science to provide actionable insights for substance use prevention and treatment, 2) shorten the time between data capture and data availability so that data are available real-time or near real-time, and 3) explore methods and tools that may allow for faster or better localized responses for substance use treatment and prevention. Priority will be given to projects that emphasize the use of existing data streams (e.g., electronic health records, syndromic surveillance, claims data, registry data, pharmacy dispensing, social media, and mortality records).This notice applies to subsequent receipt dates through September 8, 2025.
NIHNIH Notice of Special Interest (NOSI): Development and Implementation of Clinical Informatics Tools to Enhance Patients’ Use of Genomic Information--This encourages applications to develop and implement patient-facing genomic-based clinical informatics tools that facilitate or enhance patient-provider electronic communication, patient tracking and registry functions, patient self-management and support, provider electronic prescribing, test tracking, referral tracking, and health care decision-making.This notice applies to subsequent receipt dates through September 24, 2025.
NIHNIH Notice of Special Interest (NOSI): Research on Addressing Violence to Improve Health Outcomes--This encourages novel intervention research aimed at developing, refining, adapting, and testing interventions focused on preventing violence or addressing acute and chronic effects of violence on physical and behavioral health. Effectiveness, implementation, and hybrid effectiveness-implementation designs are encouraged, as appropriate to the research questions proposed.This notice applies to subsequent receipt dates through October 5, 2025.
NIHNIH National Library of Medicine (NLM) Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional)--This focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and personal wellness. The scope of NLM's interest in these research domains is broad, with emphasis on new and innovative methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, scalable, and reusable/reproducible approaches to discovery, curation, analysis, organization, and management of health-related digital objects.This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through October 5, 2025.
NIHNIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required)--This invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to the National Institute on Aging (NIA)'s research mission. Information about NIA's mission can be found on the NIA website.This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through October 5, 2025.
NIHNIH NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)--This supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.This notice applies to due dates on or after February 22, 2024 and subsequent receipt dates through October 17, 2025.
NIHNIH HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose--This supports research focusing on the identification of druggable new targets and the discovery of optimizable probes for the development of safe and efficacious medications to prevent and treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities.
R01 Clinical Trial Not Allowed
R21 Clinical Trial Not Allowed
This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through January 8, 2026.
NIHNIH Notice of Special Interest (NOSI): Computational and Statistical Methods to Enhance Discovery from Health Data--The National Library of Medicine (NLM) invites research grant applications that propose innovative state-of-the-art methods and generalizable approaches to address problems with large health data sets or analytic tools, whether the data are obtained from electronic health records, public health data sets, biomedical imaging, omics repositories, literature, and social media data, or other biomedical or social/behavioral data sets. Applications in response to this NOSI are expected to help address AI ethical issues and mitigate algorithm bias caused by data problems.This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through January 8, 2026.
NIHNIH Notice of Special Interest (NOSI): Impact of Policy Interventions Aimed at Addressing Social Determinants of Health to Improve Functioning and Well-being for People with Serious Mental Illnesses--This will fund research on the impact of social and economic policy interventions that address social determinants of health (SDOH) on improvements in access and engagement with mental health treatment, mental health functioning, and quality of life for people with serious mental illnesses, with special attention to understanding the underlying mediators/change mechanisms of those policies on outcomes.This notice applies to due dates on or after June 5, 2024, and subsequent receipt dates through January 9, 2026.
NIHNIH Innovations to Optimize HIV Prevention and Care Continuum Outcomes--The National Institute of Mental Health (NIMH) invites applications that propose to advance innovative research to optimize HIV prevention, treatment, and care. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention or care continuum, large-scale intervention efficacy or effectiveness trials, implementation science studies, or data science approaches to optimize HIV prevention, treatment, and care.
R01 Clinical Trial Optional: For applications with preliminary data or those including longitudinal analysis, advanced modeling, large-scale clinical trials or implementation science studies.
R21 Clinical Trial Optional: For exploratory, novel studies that break new ground, extend previous discoveries in new directions or result in novel techniques or models.
R34 Clinical Trial Optional: For applications proposing the initial development and pilot testing of a clinical trial or formative implementation research.
This notice applies to due dates on or after May 9, 2024 and subsequent receipt dates through January 9, 2026.
NIHNIH Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required)--Invites applications for implementation of investigator-initiated clinical trials requiring an extended project period of 6 or 7 years. The trials can be any phase, must be hypothesis-driven, and related to the research mission of the participating IC [National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Aging (NIA)]. Consultation with IC staff is strongly encouraged prior to the submission of the clinical trial implementation application. This notice applies to due dates on or after January 16, 2024 and subsequent receipt dates through January 13, 2026.
NIHNIH BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed)--Seeks applications for proof-of-concept testing and development of new technologies and novel approaches for recording and modulation of neural cells and circuits, to address major challenges and enable transformative understanding of dynamic signaling in the central nervous system. Preliminary feasibility data are not required, and it is expected that the proposed research may be high-risk, but if successful could profoundly change the course of neuroscience research.This Notice applies to due dates on or after January 19, 2024 and subsequent receipt dates through January 20, 2026.
NIHNIH BRAIN Initiative: Optimization of Instrumentation and Device Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed)--This seeks applications to optimize instrumentation and device technologies for recording and modulation of neural cells and circuits, to address major challenges and to enable transformative understanding of dynamic signaling in the central nervous system. It is expected that the proposed technologies and approaches have previously demonstrated their transformative potential through initial proof-of-concept testing, and are ready for accelerated refinement through iterative engineering and end-user feedback, appropriate for a path towards sustainable dissemination and user-friendly incorporation into routine neuroscience research.This Notice applies to due dates on or after January 19, 2024 and subsequent receipt dates through January 20, 2026.
NIHNIH Notice of Special Interest (NOSI): Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R01, R21, R03)--National Institute on Drug Abuse (NIDA) seeks research on rigorous hypothesis-driven and theory-based study designs and data analytic methods that will support a new generation of patient centered addiction health services research.This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through February 5, 2026.
NIHNIH Notice of Special Interest (NOSI): Explainable Artificial Intelligence for Decoding and Modulating Neural Circuit Activity Linked to Behavior--The eXplainable Artificial Intelligence (XAI) framework aims to provide strong predictive value along with a mechanistic understanding of AI solutions by combining machine learning techniques with effective explanatory techniques. This NOSI solicits applications in the area of XAI applied to neuroscientific questions of encoding, decoding, and modulation of neural circuits linked to behavior. This NOSI encourages collaborations between computationally and experimentally focused investigators. This NOSI seeks the development of machine learning algorithms that are able to mechanistically explain how experimental manipulations affect cognitive, affective, or social processing in humans or animals.This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through February 5, 2026.
NIHNIH Analytical and Clinical Validation of Biomarkers for Alzheimers Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Optional)--This invites applications to accelerate the establishment of effective and reliable biomarkers of Alzheimer’s disease (AD) and AD-related dementias (ADRD) for use in therapy/medical product discovery and development, clinical trials, and/or clinical practice. Specifically, this NOFO will support analytical and/or clinical validation of a biomarker, composite biomarker, or biomarker signature, with rigor comparable to the expectations described in the Food and Drug Administration (FDA's) Biomarker Qualification Program (BQP) or recommended by other FDA regulatory pathways. This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through February 5, 2026.
NIHNIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required)--This encourages applications for multi-center clinical trials focused on neurological emergencies. Successful applicants will collaborate and conduct the trial within the NIH SIREN Network. Multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet, and not within SIREN.This notice applies to due dates on or after February 6, 2024 and subsequent receipt dates through February 6, 2026.
NIHNIH Notice of Special Interest (NOSI): Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)--This NOSI will support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying substance use disorders (SUD), including fundamental circuitry and behavior relevant to substance use. This notice applies to due dates on or after January 7, 2024 and subsequent receipt dates through May 7, 2026.
NIHNIH Notice of Special Interest (NOSI): Priority Research Opportunities in Crisis Response Services--The National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), and Office of Research on Women’s Health (ORWH) are issuing this NOSI to outline priorities for research in crisis response services. Research is sought that is conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related (e.g., youth; adult; older adult), geographic (rural/remote settings), cultural considerations, and health disparities influence the types of care that are provided. Studies are encouraged that address the continuum of crisis service systems, as well as applications that address crisis services for children and under-resourced populations.This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through May 8, 2025.
NIHNIH NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed)--This encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the National Institute of Allergy and Infectious Diseases (NIAID) and considered high-priority by the Institute.This notice applies to due dates on or after January 16, 2024 and subsequent receipt dates through May 13, 2026.
NIHNIH Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes: Various Opportunities--This encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data.R01 Clinical Trial Not Allowed: This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through June 5, 2026.
• R21 Clinical Trials Not Allowed: This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through June 16, 2026.
NIHNIH Social disconnection and Suicide Risk in Late Life--This is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Mechanisms to be considered exist at multiple levels of analysis, including but not limited to neurobiological, behavioral, and environmental.R01 Clinical Trial Not Allowed: This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through June 5, 2026.
• R21 Clinical Trials Not Allowed: This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through June 16, 2026.
NIHNIH BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21 Clinical Trial Not Allowed)--This seeks applications for unique and innovative recording and/or modulation technologies that are in the earliest stage of development, including new and untested ideas that are in the initial stages of conceptualization. Some projects may aim to increase recording or modulation capabilities by many orders of magnitude, while others may aim to improve the precision and selectivity of recording or modulation (also referred to as stimulation, perturbation, or manipulation). A wide range of modalities are appropriate including acoustic, chemical, electrical, magnetic, and optical, as well as the use of genetic tools.This notice applies to due dates on or after June 18, 2024 and subsequent receipt dates through June 15, 2026.
NIHNIH Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment --R01 Clinical Trial Optional: Studies proposed should identify and validate new neuromodulation targets and provide a comprehensive understanding of the behavioral and neurobiological effects of stimulation to these targets and their constituent brain networks.This notice applies to due dates on or after January 16, 2024 and subsequent receipt dates through August 14, 2026.
R01 Basic Experimental Studies with Humans Required: For studies that meet both the definition of basic research and the NIH definition of a clinical trial. Types of studies that should submit include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.
R61/R33 Clinical Trial Optional: Supports applications that are expected to be exploratory and developmental in nature. As such, these studies may involve considerable risk of failure but may lead to a breakthrough in a particular area that could have a major impact on SUD research involving NIBS.
NIHNIH Notice of Special Interest (NOSI): Promoting implementation research to address HIV-associated comorbidities and risk factors within well-established cohorts (R01 Clinical Trial Optional)--This seeks to support dissemination and implementation (D&I) research proposals leveraging well-established cohorts of people living with HIV (PLWH) to increase the acceptability, feasibility, implementation, scale-up, scale-out, and sustainability of evidence-based interventions (EBIs) that target comorbid conditions and diseases. This NOSI hopes to promote new or existing collaborative efforts between observational, interventional, and D&I scientists, which is a crucial next step to ensure maximal public health impact of clinical trial and cohort studies. Investigators are encouraged to utilize lessons learned from ongoing or legacy cohort studies alongside other data sources to strengthen D&I research projects targeting PLWH. Further, there are opportunities to evaluate both the effectiveness and D&I outcomes of the selected EBIs, based on the level evidence to support their implementation.This notice applies to due dates on or after October 5, 2023 and subsequent receipt dates through September 7, 2026.
NIHNIH Notice of Special Interest (NOSI): Mental Health Comorbidities in HIV Prevention and Treatment--This NOSI solicits applications focused on understanding and addressing the impact of mental health comorbidities, including mental health disorders, violence, and trauma, on HIV prevention and treatment outcomes.This notice applies to due dates on or after September 7, 2023 and subsequent receipt dates through September 8, 2026.
NIHNIH Notice of Special Interest (NOSI): Intersectional Stigma and Discrimination (ISD), or Other Social and Structural Determinants of Health (SSDOH) in HIV Prevention and Treatment--This NOSI solicits theoretically- and empirically-driven research applications which will: 1) advance measurements and understanding of HIV-related ISD or intersectional social-structural factors to examine the mechanisms and pathways by which they are barriers to HIV prevention and HIV treatment; 2) develop and test interventions to address their impact to improve HIV prevention and HIV treatment outcomes; or 3) conduct implementation science research of evidence-based interventions.This notice applies to due dates on or after September 7, 2023 and subsequent receipt dates through September 8, 2026.
NIHNIH R21: Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)--The purpose of is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD).This notice applies to due dates on or after October 16, 2023 and subsequent receipt dates through September 8, 2026.
NIHNIH Notice of Special Interest (NOSI): Research on HIV-associated Malignancies--This NOSI calls for proposals that seek to identify specific contributions of HIV infection and its potential interaction with other oncogenic pathogens on the development and pathogenesis of malignancies, including studies that provide new information on the clinical outcomes of such cancers in the HIV-infected population. Applications responding must propose pioneering research that aligns with the HIV/AIDS Research Priorities here. This notice applies to due dates on or after September 7, 2023 and subsequent receipt dates through September 8, 2026.
NIHNIH Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 Clinical Trial Optional)--This is to advance the development of novel informatics and data science approaches that can help individuals understand and improve their health through actionable insights. The National Library of Medicine (NLM) and National Institute of Mental Health (NIMH) seek applications that further the science of personal health informatics by providing meaningful and actionable insights to individuals through innovative personal health data collection, integration, analysis, and personalized risk assessments and interpretation.This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through October 5, 2026.
NIHNIH NOFO - Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional)--This seeks to support the rigorous assessment of barriers to quality cancer treatment and follow-up care for sexual and gender minority (SGM) cancer survivors. The opportunity is intended to address a critical need for improved care delivery and outcomes for SGM cancer survivors. The goal is to address the disease burden in an underserved and understudied population that is at higher risk of poorer health outcomes.This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through October 5, 2026.
NIHNIH: National Cancer Institute's (NCI) Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)--The NCI is soliciting research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the Division of Cancer Treatment and Diagnosis (DCTD), and Office of HIV and AIDS Malignancies (OHAM). The proposed project must involve at least 1 clinical trial related to the scientific interests of one or more of the following research programs: Cancer Therapy Evaluation Program, Cancer Imaging Program, Cancer Diagnosis Program, Radiation Research Program, Complementary and Alternative Medicine Program and/or the HIV and AIDS Malignancies Research Programs. Applicants may propose to conduct an early phase trial by itself, or in combination with another research aim(s) as appropriate. This opportunity does not accept Phase III clinical trials.This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through October 5, 2026.
NIHNIH: Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)--This supports investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this NOFO must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this NOFO and the application instructions. This NOFO does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients.This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through October 5, 2026.
NIHNIH Notice of Special Interest (NOSI): Assessing Real-World Effectiveness and Implementation of Telehealth-Guided Provider-to-Provider Communication among Rural Communities--This NOSI is intended to support the use of the telehealth interventions and tools aimed at the prevention, management and treatment of heart, lung, blood, and sleep conditions, and of cancer in rural communities. For the purpose of this NOSI, provider-to-provider telehealth (PPT) is defined broadly to include any health technology meant to connect healthcare providers to one another for the care of patients (e.g., video, chat or audio consults with a clinical specialist for patients under the care of a primary care clinician located in another healthcare facility). This notice applies to due dates on or after October 5, 2023 and subsequent receipt dates through October 9, 2026.
NIHNIH Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (FASD): Various Opportunities--R61/R33 Clinical Trial Optional: This is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through October 16, 2026.
--R34 Clinical Trial Optional: This R34 planning grant applications focuses on prevention and intervention strategies for FASD throughout the lifespan. The intent is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through October 16, 2026.
NIHNIH Ethical, Legal and Social Implications (ELSI): Various Opportunities--Small Research Grant (R03 Clinical Trial Optional): This is for research that examines the ELSI of human genetic or genomic research. Applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This notice applies to due dates on or after February 19, 2024 and subsequent receipt dates through October 16, 2026.
--Exploratory/Developmental Research Grant (R21 Clinical Trial Optional): This is for studies of the ELSI of human genetic or genomic research. Applications may propose studies using either single or mixed methods, that break new ground, extend previous discoveries in new directions, or develop preliminary data in preparation for larger studies.This notice applies to due dates on or after February 20, 2024 and subsequent receipt dates through October 20 2026.
--Research (R01 Clinical Trial Optional): This is for applications that propose to study the ELSI of human genetic or genomic research. Applications may propose studies using either single or mixed methods. Approaches may include but are not limited to empirical qualitative and quantitative methods, and conceptual, legal, and normative analyses.This notice applies to due dates on or after February 20, 2024 and subsequent receipt dates through October 20 2026.
NIHNIH: Notice of Special Interest (NOSI): Development of Organotypic Culture Models for Transplantation Immunology Research--This Notice of Special Interest (NOSI) encourages applications that focus on the development and validation of tissue-, stem-, or progenitor-cell-derived “3D” organotypic culture models (OCM) for transplantation immunology research. This will support applications that focus on development of allogeneic or xenogeneic OCM to study immunologic features of transplant-related diseases or conditions.This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through November 16, 2026.
NIHNIH Notice of Special Interest (NOSI): Exploratory Cancer Immunology Projects and Technologies (ExCITe)--This encourages R21 applications proposing innovative high-risk/high-reward research projects, that test novel hypotheses or develop novel technologies, to advance our understanding of cancer immunology. ExCITe studies may involve considerable risk but have the potential to lead to research breakthroughs or the development of novel techniques, agents, methodologies, models, or applications that could have a major impact in cancer immunology and cancer immunotherapy research.This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through November 17, 2026.
NIHNIH Notice of Special Interest: Leveraging Existing and Accessible Datasets for Implementation Research Strategies and Testing - LEAD FIRST--This promotes the use of existing and accessible datasets to inform community-engaged dissemination and implementation (D&I) research on heart, lung, blood and sleep conditions to advance health equity. It encourages applications for D&I research that use existing community-level datasets as well as community insights to: 1) Hone in on HLBS conditions that are of high priority for the community; and 2) Hypothesize barriers and facilitators that could impact the uptake & sustainability of evidence-based interventions (EBIs) for these HLBS conditions; and/or, 3) Select, develop and test D&I strategies based on community context.This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through January 7, 2027.
NIHNIH: Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional) --This notice of funding opportunity (NOFO) is to encourage theoretically driven pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) services research examining questions specific to the prevention of substance use. The latter may include pilot studies of strategies or approaches to intervention, and/or other service system-based research to address areas such as economics, funding, service quality and engagement. In addition to the prevention of substance use, misuse and disorder, other outcomes of interest for the research supported through this NOFO include a reduction in negative sequalae of use, such as deaths related to impaired driving, suicidal behavior (e.g., nonfatal and fatal attempts), and substance-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings.This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through January 07, 2027.
NIHNIH Notice of Special Interest (NOSI): Supporting Exploratory/Developmental Research Focused on National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Core Mission Areas--This will provide support for innovative projects that introduce novel scientific ideas, model systems, tools, agents, targets, and technologies that have the potential for significant impact, and to substantially advance research within the NIAMS mission. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs of high value to the NIAMS research community.This notice applies to due dates on or after June 16, 2023 and subsequent receipt dates through January 8, 2027.
NIHNIH Notice of Special Interest (NOSI): Advancing Data Science Research in HIV: Responding to a Dynamic, Complex, and Evolving HIV Epidemic with Artificial Intelligence/Machine Learning--This seeks to advance data science research in HIV by encouraging the generation of cutting-edge synthetic datasets, artificial intelligence, and machine learning approaches to expand our capacity to address the dynamic, complex, and evolving HIV epidemic. Team science approaches where the strength and expertise of multiple individuals across data and computational sciences, biostatistics, behavioral and social sciences, computer science, and HIV prevention and care, among others, is strongly encouraged. For the purposes of this announcement, AI/ML refers to AI and its subsets (machine learning, deep learning, neural networks, natural language processing).This notice applies to due dates on or after January 7, 2024 and subsequent receipt dates through January 8, 2027.
NIHNIH Notice of Special Interest (NOSI): Behavioral Tasks Targeting Brain Systems Relevant to Anhedonia--This is to encourage research on task-based behavioral measures that engage brain systems relevant to anhedonia. These behavioral measures are expected to be used as a proxy for brain target engagement, therefore neuroimaging or other brain measures with similar spatial resolution should be used to demonstrate that the proposed behavioral tasks engage brain systems relevant to anhedonia. The goal is to identify a battery of behavioral tasks that can be used as quantitative tools for future use in the evaluation of dysfunction within domains of mental health relevant to anhedonia and for future treatment development.This notice applies to due dates on or after February 5, 2024, and subsequent receipt dates through January 8, 2027.
NIHNIH Notice of Special Interest (NOSI): Advancing Genomic Technology Development for Research and Clinical Application--This is to encourage applications focused on developing novel laboratory-focused tools and technologies that enable new lines of scientific inquiry and advance research or clinical applications in human genomics.This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through January 10, 2027.
NIHNIH: NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.This Notice of Funding Opportunity (NOFO) encourages cooperative agreement applications for implementation of investigator-initiated, high-risk clinical trials and mechanistic studies associated with high-risk clinical trials. Mechanistic work in clinical trials may be of great value because it promotes the understanding of human diseases and the development of future therapeutic modalities.This notice applies to due dates on or after May 13, 2024 and subsequent receipt dates through January 13, 2027.
NIHNIH Notice of Special Interest (NOSI): Fundamental Mechanisms and Functions of Co-transmission in the Brain--This NOSI encourages research studies in animals that systematically characterize forms of co-transmission, identify neurobiological and environmental factors influencing co-transmission, and examine the functional consequences of co-transmission within circuits supporting complex behaviors. The study of co-transmission will further our understanding of the heterogeneity of neuronal cell types, their neuromodulatory actions, and reveal novel mechanisms that could be leveraged to fine-tune neural circuits. Understanding how therapeutic candidates influence co-transmitter release may provide novel insight into their mechanisms of action, off-target effects, and lead to the development of new treatment targets.This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through February 4, 2027.
NIHNIH: Multidisciplinary Studies of HIV/AIDS and Aging --This opportunity invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives:
1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and
2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approach.
• R21 Clinical Trial Optional: This notice applies to due dates on or after June 16, 2024 and subsequent receipt dates through May 7, 2027.
• R01 Clinical Trial Optional: This notice applies to due dates on or after June 5, 2024 and subsequent receipt dates through May 7, 2027.
NIHNIH Notice of Special Interest (NOSI): Neuromodulatory Control of Circuits Underlying Mental Health Relevant Behaviors--This NOSI solicits applications seeking to understand how neuromodulatory signals dynamically control and coordinate neural circuit responses in real-time during complex mental health relevant behaviors including cognitive, social, and affective functions. These studies are expected to utilize recent tools that enable precise assessment of spatiotemporal dynamics of extracellular release or receptor activation of neuromodulators with simultaneous causal interrogation of neural activity and behavioral responses.This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through May 10, 2027.
NIHNIH Notice of Special Interest (NOSI): Advancing Research to Address the Heterogeneity of Obesity Risk, Related Health Outcomes, and Response to Treatment--This is to support research applications that address knowledge and portfolio gaps regarding the role of obesity in disease development. Understanding the heterogeneity of obesity is necessary for precision and targeted implementation of obesity prevention and treatment interventions. Responsive proposals would include those aiming to investigate biological or nonbiological mechanisms through which adiposity differentially affects health. Other responsive applications might include those evaluating heterogeneity in response to obesity prevention and treatment, based on biological (e.g., genetic), behavioral, and/or racial/ethnic factors.This notice applies to due dates on or after October 5, 2023 and subsequent receipt dates through September 7, 2027.